Amyris (AMRSQ) 10-Q 15 Nov 18 2018 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Nov. 09, 2018
Document Information [Line Items]
Entity Registrant Name	AMYRIS, INC.
Entity Central Index Key	1,365,916
Trading Symbol	amrs
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		71,910,536
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 19,045	$ 57,059
Restricted cash	1,258	2,994
Accounts receivable, net of allowance of $642 as of September 30, 2018 and December 31, 2017	35,564	24,281
Unbilled receivable	56	9,340
Inventories	6,260	5,408
Prepaid expenses and other current assets	5,541	5,525
Total current assets	67,724	104,607
Property, plant and equipment, net	16,622	13,892
Unbilled receivable, noncurrent	9,767	7,940
Restricted cash, noncurrent	959	959
Recoverable taxes from Brazilian government entities	1,053	1,445
Other assets	26,557	22,640
Total assets	122,682	151,483
Current liabilities:
Accounts payable	11,380	15,921
Accrued and other current liabilities	27,263	29,402
Deferred revenue	6,698	4,880
Debt, current portion	61,904	36,924
Related party debt, current portion	47,020	20,019
Total current liabilities	154,265	107,146
Long-term debt, net of current portion	43,667	61,893
Related party debt, net of current portion	18,526	46,541
Derivative liabilities	98,662	119,978
Other noncurrent liabilities	8,152	10,632
Total liabilities	323,272	346,190
Commitments and contingencies (Note 9)
Stockholders’ deficit:
Preferred stock - $0.0001 par value, 5,000,000 shares authorized as of September 30, 2018 and December 31, 2017, and 14,656 and 22,171 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively
Common stock - $0.0001 par value, 250,000,000 shares authorized as of September 30, 2018 and December 31, 2017; 64,090,445 and 45,637,433 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively	6	5
Additional paid-in capital	1,202,850	1,048,274
Accumulated other comprehensive loss	(42,148)	(42,156)
Accumulated deficit	(1,367,235)	(1,206,767)
Total Amyris, Inc. stockholders’ deficit	(206,527)	(200,644)
Noncontrolling interest	937	937
Total stockholders' deficit	(205,590)	(199,707)
Total liabilities, mezzanine equity and stockholders' deficit	122,682	151,483
Contingently Redeemable Common Stock [Member]
Current liabilities:
Mezzanine Equity	$ 5,000	$ 5,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Accounts receivable, allowance	$ 642	$ 642
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	14,656	22,171
Preferred stock, shares outstanding (in shares)	14,656	22,171
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	64,090,445	45,637,433
Common stock, shares outstanding (in shares)	64,090,445	45,637,433

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenue:
Revenues	$ 14,866,000	$ 24,197,000	$ 61,058,000	$ 62,857,000
Cost and operating expenses:
Cost of products sold	8,574,000	17,637,000	19,873,000	47,684,000
Research and development	16,445,000	15,185,000	50,545,000	44,141,000
Sales, general and administrative	21,026,000	15,454,000	59,972,000	44,253,000
Total cost and operating expenses	46,045,000	48,276,000	130,390,000	136,078,000
Loss from operations	(31,179,000)	(24,079,000)	(69,332,000)	(73,221,000)
Other income (expense):
Interest expense	(8,658,000)	(7,733,000)	(25,687,000)	(29,219,000)
Gain (loss) from change in fair value of derivative instruments	(25,048,000)	(18,728,000)	(64,596,000)	9,933,000
Gain (loss) upon extinguishment of derivative liability	(1,782,000)	16,036,000	75,000	25,489,000
Gain (loss) upon extinguishment of debt		461,000	(26,000)	(3,067,000)
Other income (expense), net	(1,654,000)	(136,000)	1,282,000	(576,000)
Total other income (expense), net	(37,142,000)	(10,100,000)	(88,952,000)	2,560,000
Loss before income taxes	(68,321,000)	(34,179,000)	(158,284,000)	(70,661,000)
(Provision for) benefit from income taxes		318,000		49,000
Net loss attributable to Amyris, Inc.	(68,321,000)	(33,861,000)	(158,284,000)	(70,612,000)
Less deemed dividend on capital distribution to related parties				(8,648,000)
Less deemed dividend related to beneficial conversion feature on Series A preferred stock				(562,000)
Less deemed dividend related to beneficial conversion feature on Series B preferred stock		(634,000)		(634,000)
Less deemed dividend related to beneficial conversion feature on Series D preferred stock		(5,757,000)		(5,757,000)
Less cumulative dividends on Series A and B preferred stock	(279,000)	(2,567,000)	(1,073,000)	(4,242,000)
Net loss attributable to Amyris, Inc. common stockholders	$ (68,600,000)	$ (42,819,000)	$ (159,357,000)	$ (90,455,000)
Loss per share attributable to common stockholders, basic and diluted (in dollars per share)	$ (1.13)	$ (1.14)	$ (2.86)	$ (3.32)
Weighted-average shares of common stock outstanding used in computing loss per share of common stock, basic and diluted (in dollars per share)	$ 60,966,071	$ 37,529,694	$ 55,735,571	$ 27,280,894
Product [Member]
Revenue:
Revenues	$ 9,639,000	$ 10,996,000	$ 21,467,000	$ 28,925,000
Licenses and Royalties [Member]
Revenue:
Revenues	142,000	1,022,000	18,466,000	6,774,000
Grants and Collaborations [Member]
Revenue:
Revenues	$ 5,085,000	$ 12,179,000	$ 21,125,000	$ 27,158,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues, related party	$ 2,563	$ 2,124	$ 25,951	$ 2,998
Product [Member]
Revenues, related party	854	787	2,092	1,512
Licenses and Royalties [Member]
Revenues, related party	(39)	703	18,248	703
Grants and Collaborations [Member]
Revenues, related party	$ 1,197	$ 634	$ 4,324	$ 782

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Comprehensive loss:
Net loss attributable to Amyris, Inc.	$ (68,321)	$ (33,861)	$ (158,284)	$ (70,612)
Foreign currency translation adjustment, net of tax	670	1,402	8	303
Total comprehensive loss attributable to Amyris, Inc.	$ (67,651)	$ (32,459)	$ (158,276)	$ (70,309)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities
Net loss	$ (158,284,000)	$ (70,612,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss (gain) from change in fair value of derivative instruments	64,596,000	(9,565,000)
Amortization of debt discount	10,568,000	10,108,000
Stock-based compensation	6,115,000	3,942,000
Depreciation and amortization	3,957,000	8,124,000
Loss on disposal and impairment of property, plant and equipment	943,000	37,000
Loss (gain) on foreign currency exchange rates	34,000	(205,000)
Loss upon extinguishment of debt	26,000	3,067,000
Receipt of equity in connection with collaboration arrangements revenue		(2,660,000)
Gain upon extinguishment of derivative liability	(75,000)	(25,489,000)
Gain on change in fair value of equity investment	(3,460,000)
Changes in assets and liabilities:
Accounts receivable	(10,756,000)	(10,947,000)
Unbilled receivables	7,457,000
Inventories	(890,000)	(126,000)
Prepaid expenses and other assets	(1,781,000)	(12,962,000)
Accounts payable	(5,201,000)	3,119,000
Accrued and other liabilities	(2,216,000)	404,000
Deferred revenue	1,014,000	1,113,000
Net cash used in operating activities	(87,953,000)	(102,652,000)
Cash flows from investing activities
Sales of short-term investments, net		2,999,000
Purchases of property, plant and equipment	(6,362,000)	(487,000)
Net cash (used in) provided by investing activities	(6,362,000)	2,512,000
Cash flows from financing activities
Proceeds from exercises of warrants, net	60,544,000
Proceeds from issuance of debt, net of issuance costs	35,149,000	13,965,000
Proceeds from issuance of common stock in private placement	1,416,000
Proceeds from exercises of ESPP purchases	270,000
Proceeds from exercises of common stock options	301,000	147,000
Proceeds from issuance of convertible preferred stock		101,427,000
Payment of minimum employee taxes withheld upon net share settlement of restricted stock units	(196,000)	(87,000)
Principal payments on capital leases	(848,000)
Principal payments on debt	(41,970,000)	(26,708,000)
Net cash provided by financing activities	54,666,000	88,744,000
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(101,000)	(136,000)
Net decrease in cash, cash equivalents and restricted cash	(39,750,000)	(11,532,000)
Cash, cash equivalents and restricted cash at beginning of period	61,012,000	32,433,000
Cash, cash equivalents and restricted cash at end of the period	21,262,000	20,901,000
Cash and cash equivalents	19,045,000	15,865,000
Restricted cash, current	1,258,000	4,078,000
Restricted cash, noncurrent	959,000	958,000
Cash paid for interest	14,783,000	6,805,000
Derecognition of derivative liabilities upon exercise of warrants	57,637,000
Accrued interest added to debt principal	2,029,000	1,745,000
Acquisition of property, plant and equipment under accounts payable, accrued liabilities and notes payable	783,000	1,045,000
Financing of equipment	764,000	953,000
Issuance of convertible preferred stock upon conversion of debt		40,204,000
Issuance of common stock upon conversion of debt		28,702,000
Issuance of common stock for settlement of debt principal and interest payments		14,144,000
Financing of insurance premium under notes payable		$ 191,000

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Significant Accounting Policies [Text Block]	1. Amyris, Inc. (Amyris or the Company) is a leading industrial biotechnology company that applies its technology platform to engineer, manufacture and sell high performance, natural, sustainably-sourced products into the Health & Wellness, Clean Beauty, and Flavor & Fragrance markets. The Company's proven technology platform enables the Company to rapidly engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into large volume, high-value ingredients. The Company's biotechnology platform and industrial fermentation process replace existing complex and expensive manufacturing processes. The Company has successfully used its technology to develop and produce eight The accompanying unaudited condensed consolidated financial statements of Amyris, Inc. should be read in conjunction with the audited consolidated financial statements and notes thereto included in the 10 December 31, 2017 10 10 X. not not Liquidity The Company has incurred significant operating losses since its inception and expects to continue to incur losses and negative cash flows from operations for at least the next 12 September 30, 2018, $105.6 $59.6 December 31, 2017 $1.4 As of September 30, 2018, $21.5 $171.1 $108.9 $23.3 October November 2018, $23.3 13, November 30, 2019 $111.4 (excluding $25.0 $15.7 three September 30, 2018, not one 4, no not Cash and cash equivalents of $19.0 September 30, 2018 not one one not 12 12 may may not Significant Accounting Policies Note 1, 10 606 606” Revenue from Contracts with Customers 2016 01, Financial Instruments-Overall (Subtopic 825 10 no three nine September 30, 2018. Revenue Recognition The Company recognizes revenue from the sale of renewable products, licenses of and royalties from intellectual property, and grants and collaborative research and development services. Revenue is measured based on the consideration specified in a contract with a customer and recognized when, or as, the Company satisfies a performance obligation by transferring control over a product or service to a customer. The Company generally does not The Company accounts for a contract when it has approval and commitment to perform from both parties, the rights of the parties are identified, payment terms are established, the contract has commercial substance and collectability of the consideration is probable. Changes to contracts are assessed for whether they represent a modification or should be accounted for as a new contract. The Company considers the following indicators among others when determining whether it is acting as a principal in the transaction and recording revenue on a gross basis: (i) the Company is primarily responsible for fulfilling the promise to provide the specified goods or service, (ii) the Company has inventory risk before the specified good or service has been transferred to a customer or after transfer of control to the customer and (iii) the Company has discretion in establishing the price for the specified good or service. If a transaction does not The Company’s significant contracts and contractual terms with its customers are presented in Note 10, 8 10 The Company recognizes revenue when control has passed to the customer. The following indicators are evaluated in determining when control has passed to the customer: (i) the Company has a right to payment for the product or service, (ii) the customer has legal title to the product, (iii) the Company has transferred physical possession of the product to the customer, (iv) the customer has the significant risk and rewards of ownership of the product and (v) the customer has accepted the product. The Company’s renewable products are delivered to customers from the Company’s facilities with shipping terms typically specifying F.O.B. shipping point. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company's contracts may The following is a description of the principal goods and services from which the Company generates revenue. Renewable Product Sales Revenues from renewable product sales are recognized as a distinct performance obligation on a gross basis as the Company is acting as a principal in these transactions, with the selling price to the customer recorded net of discounts and allowances. Revenues are recognized at a point in time when control has passed to the customer, which typically is upon the renewable products leaving the Company’s facilities with the first may not not not two not Licenses and Royalties Licensing of Intellectual Property: Royalties from Licensing of Intellectual Property: When the Company’s intellectual property license is the only performance obligation, or it is the predominant performance obligation in arrangements with multiple performance obligations, the Company applies the sales-based royalty exception and revenue is estimated and recognized at a point in time when the licensee’s product sales occur. Estimates of sales-based royalty revenues are made using the most likely outcome method, which is the single amount in a range of possible amounts derived from the licensee’s historical sales volumes and sales prices of its products and recent commodity market pricing data and trends. When the Company’s intellectual property license is not not Grants and Collaborative Research and Development Services Collaborative Research and Development Services: one Collaboration agreements are evaluated at inception to determine whether the intellectual property licenses represent distinct performance obligations separate from the research and development services. If the licenses are determined to be distinct, the non-refundable upfront license fee is recognized as revenue at a point in time when the license is transferred to the licensee and the licensee is able to use and benefit from the license while the research and development service fees are recognized over time as the performance obligations are satisfied. The research and development service fees represent variable consideration. Estimates of the amount of variable consideration to include in the transaction price are made using the expected value method, which is the sum of probability-weighted amounts in a range of possible amounts. The Company only includes an amount of variable consideration in the transaction price to the extent it is probable that a significant reversal in the cumulative revenue recognized will not Collaboration agreements that include milestone payments are evaluated at inception to determine whether the milestone events are considered probable of achievement and estimates are made of the amount of the milestone payments to include in the transaction price using the most likely amount method which is the single amount in a range of possible amounts. If it is probable that a significant revenue reversal will not The Company generally invoices its collaborators on a monthly or quarterly basis, or upon the completion of the effort or achievement of a milestone, based on the terms of each agreement. Deferred revenue arises from amounts received in advance of performing the research and development activities and is recognized as revenue in future periods as the performance obligations are satisfied. Grants: The milestone payments are evaluated at inception to determine whether the milestone events are considered probable of achievement and estimates are made of the amount of the milestone payments to include in the transaction price using the most likely amount method which is the single amount in a range of possible amounts. If it is probable that a significant revenue reversal will not For descriptions of the Company's other significant accounting policies, see the Company's Annual Report on Form 10 December 31, 2017. Recent Accounting Pronouncements (a) Recent Accounting Standards, Pronouncements or Updates Recently Adopted In the nine September 30, 2018, Revenue Recognition 606 January 1, 2018. 606 606 not January 1, 2018. not 605, The Company applied ASC 606 January 1, 2018, The cumulative effect of initially applying ASC 606 January 1, 2018 $0.8 $0.8 606 605. not may The following table presents the amounts by which revenue is affected in the current reporting period by the application of ASC 606 No 606. Three Months Ended September 30, 2018 Nine Months Ended September 30, 2018 (In thousands) As Adjustments Amounts Without As Adjustments Amounts Without Renewable products $ 9,639 $ — $ 9,639 $ 21,467 $ — $ 21,467 Licenses and royalties 142 1,656 1,798 18,466 (14,091 ) 4,375 Grants and collaborations 5,085 (1,555 ) 3,530 21,125 (3,820 ) 17,305 Total revenue from all customers $ 14,866 $ 101 $ 14,967 $ 61,058 $ (17,911 ) $ 43,147 Financial Instruments January 2016, 2016 01, Financial Instruments-Overall (Subtopic 825 10 2016 01 January 1, 2018 $1.4 January 1, 2018 January 1, 2018 Classification of Cash Flow Elements August 2016, 2016 15, Statement of Cash Flows (Topic 230 2016 15 2016 15 January 1, 2018 not Restricted Cash in Statement of Cash Flows November 2016, 2016 18, Statement of Cash Flows (Topic 230 January 1, 2018 2016 18 Derecognition of Nonfinancial Assets February 2017, 2017 05, Other Income—Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610 20 606 not 1 not not not 2 not January 1, 2018 not Staff Accounting Bulletin No 118 2017 December 22, 2017, 2017 not 35% 21%, one December 31, 2017. Based on the Company’s current operations it is anticipated that the only significant current impact of the Act for the Company will be the reduction in the U.S. corporate tax rate. The Act reduces the corporate tax rate to 21 January 1, 2018. December 2017, No. 118 118 not September 30, 2018, not may one 118. September 30, 2018, not (b) Recent Accounting Standards Pronouncements or Updates Not Leases February 2016, 2016 02, Leases (Topic 842 first 2019 may 840, Leases 842, Leases may Financial Instruments with "Down Round" Features July 2017, 2017 11, Earnings Per Share (Topic 260 480 815 no first 2019 Non-employee Stock-based Compensation June 2018, 2018 07, Improvements to Nonemployee Share-Based Payment Accounting, no first 2019 not Fair Value Measurement August 2018, 2018 13, Fair Value Measurement (Topic 820 820, Fair Value Measurement 2018 13 first 2020, Use of Estimates The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the periods presented. Actual results could differ from these estimates, and such differences may Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation in the Company’s condensed consolidated financial statements and the accompanying notes to the condensed consolidated financial statements, as follows: • The condensed consolidated statements of operations previously presented license fee revenue in combination with grants and collaborations revenue, and royalties (formerly referred to as “value share”) were previously presented in combination with renewable products revenue. Licenses and royalties revenue is presented as a separate line within the condensed consolidated statements of operations. The reclassifications reflect the growth in the Company’s business model of licensing its technology and earning royalties from customers utilizing the Company’s technology in the products it produces and sells. The reclassifications had no • The condensed consolidated statements of operations and condensed consolidated statements of cash flows previously presented gains or losses upon extinguishment of derivative liabilities in combination with gains or losses from change in fair value of derivative instruments. In 2018, no • In the statements of cash flows, the prior period has been restated to reflect accounting standards changes for reporting restricted cash.

Note 2 - Balance Sheet Details

Note 2 - Balance Sheet Details	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	2. Inventories Inventories are stated at the lower of cost or net realizable value and are comprised of the following: (In thousands) September 30, December 31, Raw materials $ 1,129 $ 819 Work-in-process 929 364 Finished goods 4,202 4,225 Inventories $ 6,260 $ 5,408 Property, Plant and Equipment, Net Property, plant and equipment, net is comprised of the following: (In thousands) September 30, December 31, Machinery and equipment $ 46,725 $ 49,277 Leasehold improvements 40,703 40,036 Computers and software 10,666 9,555 Furniture and office equipment, vehicles and land 3,705 3,415 Construction in progress 19,343 17,438 121,142 119,721 Less: accumulated depreciation and amortization (104,520 ) (105,829 ) Property, plant and equipment, net $ 16,622 $ 13,892 Property, plant and equipment, net includes $4.9 $4.2 September 30, 2018 December 31, 2017, $2.1 $1.6 September 30, 2018 December 31, 2017, During the three nine September 30, 2018, $0.5 $2.1 Depreciation and amortization expense, including amortization of assets under capital leases, was $1.0 $2.7 three September 30, 2018 2017, $4.0 $8.1 nine September 30, 2018 2017, Other Assets Other assets are comprised of the following: (In thousands) September 30, December 31, Contingent consideration $ 7,805 $ 8,151 Prepaid royalty 6,847 7,409 Equity investment in SweeGen 5,313 3,233 Deposits 4,171 2,462 Goodwill 560 560 Other 1,861 825 Other assets $ 26,557 $ 22,640 Accrued and Other Current Liabilities Accrued and other current liabilities are comprised of the following: (In thousands) September 30, December 31, Payroll and related expenses $ 9,774 $ 7,238 Accrued interest 6,010 8,213 SMA relocation accrual 2,964 3,587 Tax-related liabilities 2,154 5,837 Professional services 1,402 1,894 Contract termination 1,000 — Other 3,959 2,633 Total accrued and other current liabilities $ 27,263 $ 29,402

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurement	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Financial Instruments Disclosure [Text Block]	3. Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis The following tables summarize assets and liabilities measured at fair value, and the respective fair value by input classification level within the fair value hierarchy: (In thousands) September 30, 2018 December 31, 2017 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets Money market funds $ — $ — $ — $ — $ 53,199 $ — $ — $ 53,199 Certificates of deposit — — — — 7,813 — — 7,813 Equity investment in SweeGen — 5,313 — 5,313 — — — — Total assets measured and recorded at fair value $ — $ 5,313 $ — $ 5,313 $ 61,012 $ — $ — $ 61,012 Liabilities Embedded derivatives in connection with the issuance of debt and equity instruments $ — $ — $ 9,379 $ 9,379 $ — $ — $ 4,203 $ 4,203 Freestanding derivative instruments in connection with the issuance of equity instruments — — 89,283 89,283 — — 115,775 115,775 Total liabilities measured and recorded at fair value $ — $ — $ 98,662 $ 98,662 $ — $ — $ 119,978 $ 119,978 There were no Equity Investment in SweeGen The Company holds 850,115 December 2016 September 30, 2018, $5.3 2 three nine September 30, 2018, $1.7 $3.5 2016 01 January 1, 2018 1, Derivative Liabilities Recognized in Connection with the Issuance of Debt and Equity Instruments The following table provides a reconciliation of the beginning and ending balances for the Company's derivative liabilities recognized in connection with the issuance of debt and equity instruments, measured at fair value using significant unobservable inputs (Level 3 (In thousands) Equity-related Debt-related Total Derivative Balance at December 31, 2017 $ 112,368 $ 7,610 $ 119,978 Change in fair value of derivative liabilities 49,442 15,154 64,596 Derecognition upon extinguishment of derivative liabilities (85,912 ) — (85,912 ) Balance at September 30, 2018 $ 75,898 $ 22,764 $ 98,662 The derivative liabilities recognized in connection with the issuance of equity and debt instruments represent the fair value of the make-whole provisions of the Series A and B Preferred Stock as well as the cash and anti-dilution warrants issued concurrently with the Series A, B and D Preferred Stock (see Note 6, 8 10 August 2013 2014 144A 2015 144A 4, 6, 8 10 The market-based assumptions and estimates used in applying a Monte Carlo simulation approach and Black-Scholes-Merton option value approach for valuing the derivative liabilities in connection with debt and equity instruments include amounts in the following ranges: September 30, 2018 December 31, 2017 Risk-free interest rate 2.12% - 3.01% 1.68% - 2.40% Risk-adjusted yields 13.90% - 24.03% 18.40% - 28.53% Stock price volatility 45% - 80% 45% - 80% Probability of change in control 0% - 5% 5% Stock price $7.94 $3.75 Credit spread 11.69% - 21.65% 16.63% - 26.70% Estimated conversion dates 2018 - 2025 2018 - 2025 The valuation of the embedded derivatives in connection with the issuance of debt and equity instruments and freestanding derivative instruments in connection with the issuance of equity instruments can be significantly affected by changes in valuation assumptions. For example, all other things being equal, a decrease/increase in the Company’s stock price, probability of change of control, credit spread, term to maturity/conversion or stock price volatility decreases/increases the valuation of the liabilities, whereas a decrease/increase in risk adjusted yields or risk-free interest rates increases/decreases the valuation of the liabilities. A third See Note 6, 1 10 April 2018 Changes in Fair Value Changes in the fair value of derivative liabilities measured at fair value on a recurring basis are recognized in “Gain (loss) from change in fair value of derivative instruments" in the condensed consolidated statements of operations. Assets and Liabilities Recorded at Carrying Value Financial Assets and Liabilities The carrying amounts of certain financial instruments, such as cash equivalents, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities and low market interest rates, if applicable. Loans payable, credit facilities and convertible notes are recorded at carrying value, which is representative of fair value at the date of acquisition. The Company estimates the fair value of loans payable and credit facilities using observable market-based inputs (Level 2 3 (In thousands) September 30, 2018 December 31, 2017 Fair Value Carrying Value Fair Value Carrying Value Total debt $ 166,218 $ 171,117 $ 156,900 $ 165,377

Note 4 - Debt

Note 4 - Debt	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Debt Disclosure [Text Block]	4. Net carrying amounts of debt are as follows: September 30, 2018 December 31, 2017 (In thousands) Principal Unamortized Net Balance Principal Unamortized Net Balance Nonrelated Party Convertible notes 2015 Rule 144A convertible notes $ 37,887 $ (3,268 ) $ 34,619 $ 37,887 $ (6,872 ) $ 31,015 2014 Rule 144A convertible notes 24,004 (1,445 ) 22,559 24,004 (3,170 ) 20,834 December 2017 convertible note — — — 5,000 (25 ) 4,975 August 2013 financing convertible notes 4,416 (1,709 ) 2,707 4,009 (2,918 ) 1,091 66,307 (6,422 ) 59,885 70,900 (12,985 ) 57,915 Loans payable and credit facilities GACP term loan facility 36,000 (1,489 ) 34,511 — — — Senior secured loan facility — — — 28,566 (253 ) 28,313 Ginkgo notes 12,000 (4,390 ) 7,610 12,000 (4,983 ) 7,017 Other loans payable 4,643 (1,203 ) 3,440 6,463 (1,277 ) 5,186 Other credit facilities 126 — 126 381 — 381 52,769 (7,082 ) 45,687 47,410 (6,513 ) 40,897 Subtotal nonrelated party 119,076 (13,504 ) 105,572 118,310 (19,498 ) 98,812 Related Party Related party convertible notes August 2013 financing convertible notes 23,334 205 23,539 21,711 897 22,608 2014 Rule 144A convertible notes 24,705 (1,731 ) 22,974 24,705 (3,784 ) 20,921 R&D note — — — 3,700 (18 ) 3,682 48,039 (1,526 ) 46,513 50,116 (2,905 ) 47,211 Related party loans payable DSM note 25,000 (6,474 ) 18,526 25,000 (8,039 ) 16,961 Other DSM loan 506 — 506 393 — 393 February 2016 private placement — — — 2,000 — 2,000 25,506 (6,474 ) 19,032 27,393 (8,039 ) 19,354 Subtotal related party 73,545 (8,000 ) 65,545 77,509 (10,944 ) 66,565 Total debt 192,621 (21,504 ) 171,117 195,819 (30,442 ) 165,377 Less: current portion (108,924 ) (56,943 ) Long-term debt, net of current portion $ 62,193 $ 108,434 During the nine September 30, 2018, • Senior Secured Loan Facility Repayment: June 29, 2018, $27.3 • GACP Term Loan Facility: June 29, 2018, $36.0 $35.0 4, 8 10 July 2, 2018 4, 8 10 Loans under the GACP Term Loan Facilities have a maturity date of July 1, 2021; not January 7, 2019 2015 144A 2014 144A July 1, 2021 January 12, 2019, January 12, 2019. July 1, 2019 2.5% 4.0%, 6.25%, first September 30, 2018, not September 30, 2018 December 31, 2018 no not The Company paid origination fees at closing equal to 4%, $1.4 $0.2 $25,000 $1.6 3 • August 2013 August 2018, August 2017 6, August 2013 $5.2977 $4.40 Future Minimum Payments Future minimum payments under the Company's debt agreements as of September 30, 2018 Years ending December 31 (In thousands) Convertible Notes Loans Payable and Credit Facilities Related Party Convertible Notes Related Party Loans Payable and Credit Facilities Total 2018 (remaining three months) $ 2,580 $ 1,508 $ 803 $ 1,132 $ 6,023 2019 69,333 9,068 25,508 2,500 106,409 2020 — 8,915 — 2,500 11,415 2021 — 34,178 — 27,521 61,699 2022 — 13,416 — — 13,416 Thereafter — 2,565 — — 2,565 Total future minimum payments 71,913 69,650 26,311 33,653 201,527 Less: amount representing interest (5,159 ) (16,881 ) (1,606 ) (8,146 ) (31,792 ) Add: amount mandatorily convertible into common stock upon maturity — — 24,970 — 24,970 Less: future conversion of accrued interest to principal (447 ) — (1,636 ) — (2,083 ) Present value of minimum debt payments 66,307 52,769 48,039 25,507 192,622 Less: current portion of debt principal (66,307 ) (2,739 ) (48,039 ) (507 ) (117,592 ) Noncurrent portion of debt principal $ — $ 50,030 $ — $ 25,000 $ 75,030

Note 5 - Mezzanine Equity

Note 5 - Mezzanine Equity	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Mezzanine Equity Disclosure [Text Block]	5. Mezzanine equity is comprised of the following: (In thousands) September 30, 2018 December 31, 2017 Contingently redeemable common stock $ 5,000 $ 5,000 Mezzanine equity at September 30, 2018 December 31, 2017 May 10, 2016 not third $17.10 10%.

Note 6 - Stockholders' Deficit

Note 6 - Stockholders' Deficit	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	6. Warrants In connection with various debt and equity transactions (see Note 4, 6, 8 10 nine September 30, 2018: Transaction Number Additional Exercises Number Outstanding as July 2015 private placement 81,197 — — 81,197 July 2015 related party debt exchange 2,082,010 471,204 — 2,553,214 February 2016 related party private placement 171,429 — — 171,429 May 2017 cash and dilution warrants 18,042,568 — (10,784,933 ) 7,257,635 August 2017 cash and dilution warrants 9,543,234 — (5,575,118 ) 3,968,116 April 2018 warrant exercise agreements — 3,616,174 — 3,616,174 August 2018 warrant exercise agreements — 12,097,164 — 12,097,164 Other 1,406 — — 1,406 29,921,844 16,184,542 (16,360,051 ) 29,746,335 For the nine September 30, 2018, $60.5 16,360,051 Warrant Exercises and New Warrant Issuances April 2018 On April 12, 2018, May 2017 6, 8 10 May 2017 3,616,174 $14.5 May 2017 May 2017 May 2017 May 2017 May 2017 May 2017 3,616,174 $7.00 July 12, 2019. not May 2017 May 2017 $9.4 90%, 2.16%, 1.25 $0, $7.00, $6.80. $1.9 three June 30, 2018. $11.3 $9.4 $21.9 May 2017 August 2018 In August 2018, May 2017 August 2017 6, 8 10 12.6 $46.0 May 2017 August 2017 12.1 $7.52 six 15 May 2020. not May 2017 August 2017 May 2017 August 2017 $30.1 80%, 2.57%–2.58%, 1.75 $7.52, $6.56–$6.79. three September 30, 2018, $3.6 $26.5 $30.1 $63.3 May 2017 August 2017 Temasek Funding Warrant In August 2018, August 2013 $5.2977 $4.40 4, 6, 8 10 471,204 At Market Issuance Sales Agreement On March 8, 2016, may $50.0 3 No. 333 203216 April 15, 2015. may 415 1933, 3.0% no During the three nine September 30, 2018, 0 205,168 $6.90 $1.4 April 15, 2018, zero September 30, 2018.

Note 7 - Variable-interest Enti

Note 7 - Variable-interest Entities and Unconsolidated Investments	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Variable Interest Entity Disclosure [Text Block]	7. Consolidated Variable-interest Entity The table below reflects the carrying value of the Aprinnova joint venture (JV) (see Note 7, 8 10 September 30, 2018: (In thousands) September 30, 2018 December 31, 2017 Assets $ 38,422 $ 36,781 Liabilities $ 1,960 $ 3,187 The Aprinnova JV's creditors have recourse only to the assets of the Aprinnova JV. During the three nine September 30, 2018 2017, no Unconsolidated Investments The Company's unconsolidated investments are summarized as follows: Carrying Value of Investment on (Amounts in thousands) Amyris Equity September 30, 2018 December 31, 2017 Equity-method investments: Novvi LLC 20 % $ — $ — Total Amyris BioSolutions B.V. 25 % $ — $ — Other unconsolidated equity investment: SweeGen, Inc. 3 % $ 5,313 $ 3,233

Note 8 - Net Loss Per Share Att

Note 8 - Net Loss Per Share Attributable to Common Stockholders	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Earnings Per Share [Text Block]	8. For the three nine September 30, 2018 September 30, 2017, The following table presents the calculation of basic and diluted loss per share attributable to common stockholders: Three Months Ended September 30, Nine Months Ended September 30, (In thousands, except shares and per share amounts) 2018 2017 2018 2017 Numerator: Net loss attributable to Amyris, Inc. $ (68,321 ) $ (33,861 ) $ (158,284 ) $ (70,612 ) Less deemed dividend on capital distribution to related parties — — — (8,648 ) Less deemed dividend related to beneficial conversion feature on Series A preferred stock — — — (562 ) Less deemed dividend related to beneficial conversion feature on Series B preferred stock — (634 ) — (634 ) Less deemed dividend related to beneficial conversion feature on Series D preferred stock — (5,757 ) — (5,757 ) Less cumulative dividends on Series A and B preferred stock (279 ) (2,567 ) (1,073 ) (4,242 ) Net loss attributable to Amyris, Inc. common stockholders, basic and diluted $ (68,600 ) $ (42,819 ) $ (159,357 ) $ (90,455 ) Denominator: Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted 60,966,071 37,529,694 55,735,571 27,280,894 Basic and diluted loss per share $ (1.13 ) $ (1.14 ) $ (2.86 ) $ (3.32 ) Diluted loss per share for the nine September 30, 2017 September 30, 2017 10 $125.9 $4.61. not nine September 30, 2017 The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted loss per share of common stock because including them would have been antidilutive: Three Months Ended Nine Months Ended 2018 2017 2018 2017 Period-end stock options to purchase common stock 5,449,701 949,023 5,449,701 949,023 Convertible promissory notes (1) 9,397,134 8,133,594 9,397,134 8,133,594 Period-end common stock warrants 25,986,432 31,303,080 25,986,432 31,303,080 Period-end restricted stock units 5,324,092 599,425 5,324,092 599,425 Period-end preferred stock 2,955,732 — 2,955,732 — Total potentially dilutive securities excluded from computation of diluted loss per share 49,113,091 40,985,122 49,113,091 40,985,122 ______________ ( 1 The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of the respective period end dates. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding.

Note 9 - Commitments and Contin

Note 9 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Contingencies Disclosure [Text Block]	9. Commitments Future minimum payments under the Company's lease obligations as of September 30, 2018 Years ending December 31: (In thousands) Capital Operating Total Lease 2018 (remaining three months) $ 143 $ 2,776 $ 2,919 2019 513 9,966 10,479 2020 199 7,675 7,874 2021 3 7,237 7,240 2022 — 7,410 7,410 Thereafter — 3,270 3,270 Total future minimum payments $ 858 $ 38,334 $ 39,192 Less: amount representing interest (46 ) Present value of minimum lease payments 812 Less: current portion (503 ) Long-term portion $ 309 Guarantor Arrangements In November 2010, 4, 8 10 September 30, 2018 December 31, 2017 was R$6.0 US$1.5 US$1.8 Contingencies The Company has levied indirect taxes on sugarcane-based biodiesel sales that took place several years ago by Amyris Brasil Ltda. (see Note 13, 8 10 The Company and a number of the Company’s current officers and directors are parties to four December 21, 2017, March 9, 2018. March 29, 2018, May 4, 2018 July 23, 2018, two August 30, 2018, September 4, 2018, 1, 10 The Company is subject to disputes and claims that arise or have arisen in the ordinary course of business and that have not not may not one

Note 10 - Revenue Recognition a

Note 10 - Revenue Recognition and Contract Assets and Liabilities	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Collaborative Arrangement Disclosure [Text Block]	10. Disaggregation of Revenue The following table presents revenue by major product and service, as well as by primary geographical market, based on the location of the customer: Three Months Ended September 30, (In thousands) 2018 2017 Renewable Licenses Grants and Total Renewable Licenses Grants and Total United States $ 4,884 $ — $ 626 $ 5,510 $ 5,873 $ — $ 6,141 $ 12,014 Europe 1,175 142 3,908 5,225 2,314 1,022 3,935 7,271 Asia 3,544 — — 3,544 2,773 — 125 2,898 South America 36 — 551 587 36 — 1,978 2,014 Other — — — — — — — — $ 9,639 $ 142 $ 5,085 $ 14,866 $ 10,996 $ 1,022 $ 12,179 $ 24,197 Nine Months Ended September 30, (In thousands) 2018 2017 Renewable Licenses Grants and Total Renewable Licenses Grants and Total United States $ 9,185 $ — $ 6,457 $ 15,642 $ 8,871 $ 2,673 $ 15,510 $ 27,054 Europe 6,596 18,466 11,723 36,785 5,621 1,468 9,295 16,384 Asia 5,335 — 1,000 6,335 14,242 2,633 375 17,250 South America 251 — 1,945 2,196 180 — 1,978 2,158 Other 100 — — 100 11 — — 11 $ 21,467 $ 18,466 $ 21,125 $ 61,058 $ 28,925 $ 6,774 $ 27,158 $ 62,857 Significant Revenue Agreements In connection with significant revenue agreements (see Note 10, 8 10 , the Company recognized the following revenues for the three nine September 30, 2018 2017 : Three Months Ended September 30, (In thousands) 2018 2017 Renewable Licenses Grants and Total Renewable Licenses Grants and Total DSM - related party $ 17 $ (39 ) $ 1,748 $ 1,726 $ — $ 703 $ 634 $ 1,337 Givaudan 525 — 1,500 2,025 1,331 — 1,500 2,831 Firmenich 904 181 1,212 2,297 4,525 319 1,351 6,195 Nenter — — — — 1,678 — — 1,678 DARPA — — 241 241 — — 1,252 1,252 Subtotal revenue from significant revenue agreements 1,446 142 4,701 6,289 7,534 1,022 4,737 13,293 Revenue from all other customers 8,193 — 384 8,577 3,462 — 7,442 10,904 Total revenue from all customers $ 9,639 $ 142 $ 5,085 $ 14,866 $ 10,996 $ 1,022 $ 12,179 $ 24,197 Nine Months Ended September 30, (In thousands) 2018 2017 Renewable Licenses Grants and Total Renewable Licenses Grants and Total DSM - related party $ 17 $ 18,248 $ 5,611 $ 23,876 $ 10 $ 703 $ 783 $ 1,496 Givaudan 3,710 — 4,358 8,068 1,950 — 4,500 6,450 Firmenich 1,110 218 3,698 5,026 6,178 765 4,562 11,505 Nenter — — 1,000 1,000 8,003 2,633 — 10,636 DARPA — — 5,278 5,278 — — 6,894 6,894 Subtotal revenue from significant revenue agreements 4,837 18,466 19,945 43,248 16,141 4,101 16,739 36,981 Revenue from all other customers 16,630 — 1,180 17,810 12,784 2,673 10,419 25,876 Total revenue from all customers $ 21,467 $ 18,466 $ 21,125 $ 61,058 $ 28,925 $ 6,774 $ 27,158 $ 62,857 Contract Assets and Liabilities When a contract results in revenue being recognized in excess of the amount the Company has invoiced or has the right to invoice to the customer, a contract asset is recognized. Contract assets are transferred to accounts receivable, net when the rights to the consideration become unconditional. Contract assets are presented as Unbilled Receivables on the consolidated balance sheets. Contract liabilities consist of payments received from customers, or such consideration that is contractually due, in advance of providing the product or performing services such that control has not Trade receivables related to revenue from contracts with customers are included in accounts receivable on the consolidated balance sheets, net of the allowance for doubtful accounts. Trade accounts receivable are recorded at the point of renewable product sale or in accordance with the contractual payment terms for licenses and royalties, and grants and collaborative research and development services for the amount payable by the customer to the Company for sale of goods or the performance of services. Contract Balances The following table provides information about unbilled receivables, deferred revenue, and accounts receivable from contracts with customers: (In thousands) September 30, December 31, Unbilled receivable, current $ 56 $ 9,340 Unbilled receivable, noncurrent $ 9,767 $ 7,940 Deferred revenue, current $ 6,698 $ 4,880 Deferred revenue, noncurrent $ 383 (1) $ 383 (1) Accounts receivable, net $ 35,564 $ 24,281 ______________ ( 1 September 30, 2018 December 31, 2017, Unbilled receivables relate to the Company’s right to consideration from DSM for (i) minimum future royalties and (ii) performance fees. The Company’s right to cash receipt for these minimum royalty amounts occurs on or before December 31, 2019. December 31, 2017 September 30, 2018, $7.5 Deferred revenue, current increased by $1.8 September 30, 2018 $0.8 606 January 1, 2018 $3.3 nine September 30, 2018 Remaining Performance Obligations The following table provides information regarding the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) based on the Company's existing agreements with customers as of September 30, 2018. (In thousands) As of September 30, 2018 Remaining 2018 $ 3,592 2019 9,742 2020 7,742 2021 and thereafter 672 Total from all customers $ 21,748 In accordance with the disclosure provisions of ASC 606, one $17.4

Note 11 - Related Party Transac

Note 11 - Related Party Transactions	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	11. Related Party Debt See Note 4. 1 10 September 30, 2018 December 31, 2017. Related Party Accounts Receivable and Unbilled Receivables Related party accounts receivable and unbilled receivables as of September 30, 2018 December 31, 2017 (In thousands) September 30, 2018 December 31, 2017 Accounts receivable, net: DSM $ 20,419 $ 3,483 Novvi 24 1,607 Total 120 238 $ 20,563 $ 5,328 Unbilled receivable, current: DSM $ 56 $ 9,340 Unbilled receivable, noncurrent: DSM $ 9,767 $ 7,940 Related Party Joint Ventures See Note 7, in Part I, Item 1 10 8 10 • Aprinnova joint venture with Nikko, and • TAB joint venture with Total

Note 12 - Stock-based Compensat

Note 12 - Stock-based Compensation	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	12. The Company’s stock option activity and related information for the nine September 30, 2018 Quantity of Weighted- Weighted- Aggregate Outstanding - December 31, 2017 1,338,367 $ 33.40 7.7 $ 97 Granted 4,296,337 $ 5.18 Exercised (61,750 ) $ 3.68 Forfeited or expired (123,253 ) $ 28.18 Outstanding - September 30, 2018 5,449,701 $ 11.60 9.0 $ 13,721 Vested or expected to vest after September 30, 2018 5,031,524 $ 12.14 8.9 $ 12,552 Exercisable at September 30, 2018 942,636 $ 41.25 6.7 $ 1,536 The Company’s restricted stock units (RSUs) activity and related information for the nine September 30, 2018 Quantity of Weighted- Weighted- Outstanding - December 31, 2017 683,554 $ 8.62 1.4 Awarded 4,993,022 $ 5.38 RSUs released (226,129 ) $ 10.38 RSUs forfeited (126,355 ) $ 6.16 Outstanding - September 30, 2018 5,324,092 $ 5.57 1.8 Vested or expected to vest after September 30, 2018 5,065,108 $ 5.57 1.8 Stock-based compensation expense related to options and RSUs granted to employees and non-employees during the three nine September 30, 2018 2017 Three Months Ended Nine Months Ended (In thousands) 2018 2017 2018 2017 Research and development $ 495 $ 395 $ 1,191 $ 1,320 Sales, general and administrative 2,442 863 4,924 2,622 Total stock-based compensation expense $ 2,937 $ 1,258 $ 6,115 $ 3,942 As of September 30, 2018, $35.0 3.5 The fair value of employee stock options was estimated using the following weighted-average assumptions: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Expected dividend yield — % — % — % — % Risk-free interest rate 2.8 % 2.0 % 2.7 % 2.0 % Expected term (in years) 6.87 6.20 6.85 6.10 Expected volatility 79.1 % 92.2 % 79.6 % 81.6 % In May 2018, 2010 9 4 Also in May 2018, 2010 may 1 In May 2018, 3,250,000 may December 31, 2021, December 31, 2022. four may zero 3,250,000 $5.08 Stock-based compensation expense for this award is recognized using a graded-vesting approach over the service period beginning at the grant date through December 31, 2022, September 30, 2018, $5.1 three nine September 30, 2018, $0.3 $0.4 Stock Option Award with Performance and Market Vesting Conditions: Fair value of the Company’s common stock on grant date $ 5.08 Expected volatility 70 % Risk-free interest rate 2.75 % Dividend yield 0.0 %

Note 13 - Subsequent Events

Note 13 - Subsequent Events	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	13. Conversion of August 2013 On October 16, 2018, August 2013 4, 8 10 3,448,821 Exercise of Temasek Funding Warrant On October 19, 2018, 6, 8 10 1,889,986 1,852,585 Conversion of August 2013 On November 8, 2018, August 2013 January 15, 2019, 4, 8 10 2,226,105

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Liquidity [Policy Text Block]	Liquidity The Company has incurred significant operating losses since its inception and expects to continue to incur losses and negative cash flows from operations for at least the next 12 September 30, 2018, $105.6 $59.6 December 31, 2017 $1.4 As of September 30, 2018, $21.5 $171.1 $108.9 $23.3 October November 2018, $23.3 13, November 30, 2019 $111.4 (excluding $25.0 $15.7 three September 30, 2018, not one 4, no not Cash and cash equivalents of $19.0 September 30, 2018 not one one not 12 12 may may not
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition The Company recognizes revenue from the sale of renewable products, licenses of and royalties from intellectual property, and grants and collaborative research and development services. Revenue is measured based on the consideration specified in a contract with a customer and recognized when, or as, the Company satisfies a performance obligation by transferring control over a product or service to a customer. The Company generally does not The Company accounts for a contract when it has approval and commitment to perform from both parties, the rights of the parties are identified, payment terms are established, the contract has commercial substance and collectability of the consideration is probable. Changes to contracts are assessed for whether they represent a modification or should be accounted for as a new contract. The Company considers the following indicators among others when determining whether it is acting as a principal in the transaction and recording revenue on a gross basis: (i) the Company is primarily responsible for fulfilling the promise to provide the specified goods or service, (ii) the Company has inventory risk before the specified good or service has been transferred to a customer or after transfer of control to the customer and (iii) the Company has discretion in establishing the price for the specified good or service. If a transaction does not The Company’s significant contracts and contractual terms with its customers are presented in Note 10, 8 10 The Company recognizes revenue when control has passed to the customer. The following indicators are evaluated in determining when control has passed to the customer: (i) the Company has a right to payment for the product or service, (ii) the customer has legal title to the product, (iii) the Company has transferred physical possession of the product to the customer, (iv) the customer has the significant risk and rewards of ownership of the product and (v) the customer has accepted the product. The Company’s renewable products are delivered to customers from the Company’s facilities with shipping terms typically specifying F.O.B. shipping point. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company's contracts may The following is a description of the principal goods and services from which the Company generates revenue. Renewable Product Sales Revenues from renewable product sales are recognized as a distinct performance obligation on a gross basis as the Company is acting as a principal in these transactions, with the selling price to the customer recorded net of discounts and allowances. Revenues are recognized at a point in time when control has passed to the customer, which typically is upon the renewable products leaving the Company’s facilities with the first may not not not two not Licenses and Royalties Licensing of Intellectual Property: Royalties from Licensing of Intellectual Property: When the Company’s intellectual property license is the only performance obligation, or it is the predominant performance obligation in arrangements with multiple performance obligations, the Company applies the sales-based royalty exception and revenue is estimated and recognized at a point in time when the licensee’s product sales occur. Estimates of sales-based royalty revenues are made using the most likely outcome method, which is the single amount in a range of possible amounts derived from the licensee’s historical sales volumes and sales prices of its products and recent commodity market pricing data and trends. When the Company’s intellectual property license is not not Grants and Collaborative Research and Development Services Collaborative Research and Development Services: one Collaboration agreements are evaluated at inception to determine whether the intellectual property licenses represent distinct performance obligations separate from the research and development services. If the licenses are determined to be distinct, the non-refundable upfront license fee is recognized as revenue at a point in time when the license is transferred to the licensee and the licensee is able to use and benefit from the license while the research and development service fees are recognized over time as the performance obligations are satisfied. The research and development service fees represent variable consideration. Estimates of the amount of variable consideration to include in the transaction price are made using the expected value method, which is the sum of probability-weighted amounts in a range of possible amounts. The Company only includes an amount of variable consideration in the transaction price to the extent it is probable that a significant reversal in the cumulative revenue recognized will not Collaboration agreements that include milestone payments are evaluated at inception to determine whether the milestone events are considered probable of achievement and estimates are made of the amount of the milestone payments to include in the transaction price using the most likely amount method which is the single amount in a range of possible amounts. If it is probable that a significant revenue reversal will not The Company generally invoices its collaborators on a monthly or quarterly basis, or upon the completion of the effort or achievement of a milestone, based on the terms of each agreement. Deferred revenue arises from amounts received in advance of performing the research and development activities and is recognized as revenue in future periods as the performance obligations are satisfied. Grants: The milestone payments are evaluated at inception to determine whether the milestone events are considered probable of achievement and estimates are made of the amount of the milestone payments to include in the transaction price using the most likely amount method which is the single amount in a range of possible amounts. If it is probable that a significant revenue reversal will not For descriptions of the Company's other significant accounting policies, see the Company's Annual Report on Form 10 December 31, 2017.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements (a) Recent Accounting Standards, Pronouncements or Updates Recently Adopted In the nine September 30, 2018, Revenue Recognition 606 January 1, 2018. 606 606 not January 1, 2018. not 605, The Company applied ASC 606 January 1, 2018, The cumulative effect of initially applying ASC 606 January 1, 2018 $0.8 $0.8 606 605. not may The following table presents the amounts by which revenue is affected in the current reporting period by the application of ASC 606 No 606. Three Months Ended September 30, 2018 Nine Months Ended September 30, 2018 (In thousands) As Adjustments Amounts Without As Adjustments Amounts Without Renewable products $ 9,639 $ — $ 9,639 $ 21,467 $ — $ 21,467 Licenses and royalties 142 1,656 1,798 18,466 (14,091 ) 4,375 Grants and collaborations 5,085 (1,555 ) 3,530 21,125 (3,820 ) 17,305 Total revenue from all customers $ 14,866 $ 101 $ 14,967 $ 61,058 $ (17,911 ) $ 43,147 Financial Instruments January 2016, 2016 01, Financial Instruments-Overall (Subtopic 825 10 2016 01 January 1, 2018 $1.4 January 1, 2018 January 1, 2018 Classification of Cash Flow Elements August 2016, 2016 15, Statement of Cash Flows (Topic 230 2016 15 2016 15 January 1, 2018 not Restricted Cash in Statement of Cash Flows November 2016, 2016 18, Statement of Cash Flows (Topic 230 January 1, 2018 2016 18 Derecognition of Nonfinancial Assets February 2017, 2017 05, Other Income—Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610 20 606 not 1 not not not 2 not January 1, 2018 not Staff Accounting Bulletin No 118 2017 December 22, 2017, 2017 not 35% 21%, one December 31, 2017. Based on the Company’s current operations it is anticipated that the only significant current impact of the Act for the Company will be the reduction in the U.S. corporate tax rate. The Act reduces the corporate tax rate to 21 January 1, 2018. December 2017, No. 118 118 not September 30, 2018, not may one 118. September 30, 2018, not (b) Recent Accounting Standards Pronouncements or Updates Not Leases February 2016, 2016 02, Leases (Topic 842 first 2019 may 840, Leases 842, Leases may Financial Instruments with "Down Round" Features July 2017, 2017 11, Earnings Per Share (Topic 260 480 815 no first 2019 Non-employee Stock-based Compensation June 2018, 2018 07, Improvements to Nonemployee Share-Based Payment Accounting, no first 2019 not Fair Value Measurement August 2018, 2018 13, Fair Value Measurement (Topic 820 820, Fair Value Measurement 2018 13 first 2020,
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the periods presented. Actual results could differ from these estimates, and such differences may
Reclassification, Policy [Policy Text Block]	Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation in the Company’s condensed consolidated financial statements and the accompanying notes to the condensed consolidated financial statements, as follows: • The condensed consolidated statements of operations previously presented license fee revenue in combination with grants and collaborations revenue, and royalties (formerly referred to as “value share”) were previously presented in combination with renewable products revenue. Licenses and royalties revenue is presented as a separate line within the condensed consolidated statements of operations. The reclassifications reflect the growth in the Company’s business model of licensing its technology and earning royalties from customers utilizing the Company’s technology in the products it produces and sells. The reclassifications had no • The condensed consolidated statements of operations and condensed consolidated statements of cash flows previously presented gains or losses upon extinguishment of derivative liabilities in combination with gains or losses from change in fair value of derivative instruments. In 2018, no • In the statements of cash flows, the prior period has been restated to reflect accounting standards changes for reporting restricted cash.

Note 1 - Basis of Presentatio_2

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]	Three Months Ended September 30, 2018 Nine Months Ended September 30, 2018 (In thousands) As Adjustments Amounts Without As Adjustments Amounts Without Renewable products $ 9,639 $ — $ 9,639 $ 21,467 $ — $ 21,467 Licenses and royalties 142 1,656 1,798 18,466 (14,091 ) 4,375 Grants and collaborations 5,085 (1,555 ) 3,530 21,125 (3,820 ) 17,305 Total revenue from all customers $ 14,866 $ 101 $ 14,967 $ 61,058 $ (17,911 ) $ 43,147

Note 2 - Balance Sheet Details

Note 2 - Balance Sheet Details (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Inventory, Current [Table Text Block]	(In thousands) September 30, December 31, Raw materials $ 1,129 $ 819 Work-in-process 929 364 Finished goods 4,202 4,225 Inventories $ 6,260 $ 5,408
Property, Plant and Equipment [Table Text Block]	(In thousands) September 30, December 31, Machinery and equipment $ 46,725 $ 49,277 Leasehold improvements 40,703 40,036 Computers and software 10,666 9,555 Furniture and office equipment, vehicles and land 3,705 3,415 Construction in progress 19,343 17,438 121,142 119,721 Less: accumulated depreciation and amortization (104,520 ) (105,829 ) Property, plant and equipment, net $ 16,622 $ 13,892
Schedule of Other Assets, Noncurrent [Table Text Block]	(In thousands) September 30, December 31, Contingent consideration $ 7,805 $ 8,151 Prepaid royalty 6,847 7,409 Equity investment in SweeGen 5,313 3,233 Deposits 4,171 2,462 Goodwill 560 560 Other 1,861 825 Other assets $ 26,557 $ 22,640
Schedule of Accrued and Other Current Liabilities [Table Text Block]	(In thousands) September 30, December 31, Payroll and related expenses $ 9,774 $ 7,238 Accrued interest 6,010 8,213 SMA relocation accrual 2,964 3,587 Tax-related liabilities 2,154 5,837 Professional services 1,402 1,894 Contract termination 1,000 — Other 3,959 2,633 Total accrued and other current liabilities $ 27,263 $ 29,402

Note 3 - Fair Value Measureme_2

Note 3 - Fair Value Measurement (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	(In thousands) September 30, 2018 December 31, 2017 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets Money market funds $ — $ — $ — $ — $ 53,199 $ — $ — $ 53,199 Certificates of deposit — — — — 7,813 — — 7,813 Equity investment in SweeGen — 5,313 — 5,313 — — — — Total assets measured and recorded at fair value $ — $ 5,313 $ — $ 5,313 $ 61,012 $ — $ — $ 61,012 Liabilities Embedded derivatives in connection with the issuance of debt and equity instruments $ — $ — $ 9,379 $ 9,379 $ — $ — $ 4,203 $ 4,203 Freestanding derivative instruments in connection with the issuance of equity instruments — — 89,283 89,283 — — 115,775 115,775 Total liabilities measured and recorded at fair value $ — $ — $ 98,662 $ 98,662 $ — $ — $ 119,978 $ 119,978
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	(In thousands) Equity-related Debt-related Total Derivative Balance at December 31, 2017 $ 112,368 $ 7,610 $ 119,978 Change in fair value of derivative liabilities 49,442 15,154 64,596 Derecognition upon extinguishment of derivative liabilities (85,912 ) — (85,912 ) Balance at September 30, 2018 $ 75,898 $ 22,764 $ 98,662
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	September 30, 2018 December 31, 2017 Risk-free interest rate 2.12% - 3.01% 1.68% - 2.40% Risk-adjusted yields 13.90% - 24.03% 18.40% - 28.53% Stock price volatility 45% - 80% 45% - 80% Probability of change in control 0% - 5% 5% Stock price $7.94 $3.75 Credit spread 11.69% - 21.65% 16.63% - 26.70% Estimated conversion dates 2018 - 2025 2018 - 2025
Fair Value, by Balance Sheet Grouping [Table Text Block]	(In thousands) September 30, 2018 December 31, 2017 Fair Value Carrying Value Fair Value Carrying Value Total debt $ 166,218 $ 171,117 $ 156,900 $ 165,377

Note 4 - Debt (Tables)

Note 4 - Debt (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Debt [Table Text Block]	September 30, 2018 December 31, 2017 (In thousands) Principal Unamortized Net Balance Principal Unamortized Net Balance Nonrelated Party Convertible notes 2015 Rule 144A convertible notes $ 37,887 $ (3,268 ) $ 34,619 $ 37,887 $ (6,872 ) $ 31,015 2014 Rule 144A convertible notes 24,004 (1,445 ) 22,559 24,004 (3,170 ) 20,834 December 2017 convertible note — — — 5,000 (25 ) 4,975 August 2013 financing convertible notes 4,416 (1,709 ) 2,707 4,009 (2,918 ) 1,091 66,307 (6,422 ) 59,885 70,900 (12,985 ) 57,915 Loans payable and credit facilities GACP term loan facility 36,000 (1,489 ) 34,511 — — — Senior secured loan facility — — — 28,566 (253 ) 28,313 Ginkgo notes 12,000 (4,390 ) 7,610 12,000 (4,983 ) 7,017 Other loans payable 4,643 (1,203 ) 3,440 6,463 (1,277 ) 5,186 Other credit facilities 126 — 126 381 — 381 52,769 (7,082 ) 45,687 47,410 (6,513 ) 40,897 Subtotal nonrelated party 119,076 (13,504 ) 105,572 118,310 (19,498 ) 98,812 Related Party Related party convertible notes August 2013 financing convertible notes 23,334 205 23,539 21,711 897 22,608 2014 Rule 144A convertible notes 24,705 (1,731 ) 22,974 24,705 (3,784 ) 20,921 R&D note — — — 3,700 (18 ) 3,682 48,039 (1,526 ) 46,513 50,116 (2,905 ) 47,211 Related party loans payable DSM note 25,000 (6,474 ) 18,526 25,000 (8,039 ) 16,961 Other DSM loan 506 — 506 393 — 393 February 2016 private placement — — — 2,000 — 2,000 25,506 (6,474 ) 19,032 27,393 (8,039 ) 19,354 Subtotal related party 73,545 (8,000 ) 65,545 77,509 (10,944 ) 66,565 Total debt 192,621 (21,504 ) 171,117 195,819 (30,442 ) 165,377 Less: current portion (108,924 ) (56,943 ) Long-term debt, net of current portion $ 62,193 $ 108,434
Schedule of Long-term Debt Instruments [Table Text Block]	Years ending December 31 (In thousands) Convertible Notes Loans Payable and Credit Facilities Related Party Convertible Notes Related Party Loans Payable and Credit Facilities Total 2018 (remaining three months) $ 2,580 $ 1,508 $ 803 $ 1,132 $ 6,023 2019 69,333 9,068 25,508 2,500 106,409 2020 — 8,915 — 2,500 11,415 2021 — 34,178 — 27,521 61,699 2022 — 13,416 — — 13,416 Thereafter — 2,565 — — 2,565 Total future minimum payments 71,913 69,650 26,311 33,653 201,527 Less: amount representing interest (5,159 ) (16,881 ) (1,606 ) (8,146 ) (31,792 ) Add: amount mandatorily convertible into common stock upon maturity — — 24,970 — 24,970 Less: future conversion of accrued interest to principal (447 ) — (1,636 ) — (2,083 ) Present value of minimum debt payments 66,307 52,769 48,039 25,507 192,622 Less: current portion of debt principal (66,307 ) (2,739 ) (48,039 ) (507 ) (117,592 ) Noncurrent portion of debt principal $ — $ 50,030 $ — $ 25,000 $ 75,030

Note 5 - Mezzanine Equity (Tabl

Note 5 - Mezzanine Equity (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Mezzanine Equity Table [Table Text Block]	(In thousands) September 30, 2018 December 31, 2017 Contingently redeemable common stock $ 5,000 $ 5,000

Note 6 - Stockholders' Deficit

Note 6 - Stockholders' Deficit (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Transaction Number Additional Exercises Number Outstanding as July 2015 private placement 81,197 — — 81,197 July 2015 related party debt exchange 2,082,010 471,204 — 2,553,214 February 2016 related party private placement 171,429 — — 171,429 May 2017 cash and dilution warrants 18,042,568 — (10,784,933 ) 7,257,635 August 2017 cash and dilution warrants 9,543,234 — (5,575,118 ) 3,968,116 April 2018 warrant exercise agreements — 3,616,174 — 3,616,174 August 2018 warrant exercise agreements — 12,097,164 — 12,097,164 Other 1,406 — — 1,406 29,921,844 16,184,542 (16,360,051 ) 29,746,335

Note 7 - Variable-interest En_2

Note 7 - Variable-interest Entities and Unconsolidated Investments (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Variable Interest Entities [Table Text Block]	(In thousands) September 30, 2018 December 31, 2017 Assets $ 38,422 $ 36,781 Liabilities $ 1,960 $ 3,187
Unconsolidated Investments [Table Text Block]	Carrying Value of Investment on (Amounts in thousands) Amyris Equity September 30, 2018 December 31, 2017 Equity-method investments: Novvi LLC 20 % $ — $ — Total Amyris BioSolutions B.V. 25 % $ — $ — Other unconsolidated equity investment: SweeGen, Inc. 3 % $ 5,313 $ 3,233

Note 8 - Net Loss Per Share A_2

Note 8 - Net Loss Per Share Attributable to Common Stockholders (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, (In thousands, except shares and per share amounts) 2018 2017 2018 2017 Numerator: Net loss attributable to Amyris, Inc. $ (68,321 ) $ (33,861 ) $ (158,284 ) $ (70,612 ) Less deemed dividend on capital distribution to related parties — — — (8,648 ) Less deemed dividend related to beneficial conversion feature on Series A preferred stock — — — (562 ) Less deemed dividend related to beneficial conversion feature on Series B preferred stock — (634 ) — (634 ) Less deemed dividend related to beneficial conversion feature on Series D preferred stock — (5,757 ) — (5,757 ) Less cumulative dividends on Series A and B preferred stock (279 ) (2,567 ) (1,073 ) (4,242 ) Net loss attributable to Amyris, Inc. common stockholders, basic and diluted $ (68,600 ) $ (42,819 ) $ (159,357 ) $ (90,455 ) Denominator: Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted 60,966,071 37,529,694 55,735,571 27,280,894 Basic and diluted loss per share $ (1.13 ) $ (1.14 ) $ (2.86 ) $ (3.32 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended Nine Months Ended 2018 2017 2018 2017 Period-end stock options to purchase common stock 5,449,701 949,023 5,449,701 949,023 Convertible promissory notes (1) 9,397,134 8,133,594 9,397,134 8,133,594 Period-end common stock warrants 25,986,432 31,303,080 25,986,432 31,303,080 Period-end restricted stock units 5,324,092 599,425 5,324,092 599,425 Period-end preferred stock 2,955,732 — 2,955,732 — Total potentially dilutive securities excluded from computation of diluted loss per share 49,113,091 40,985,122 49,113,091 40,985,122

Note 9 - Commitments and Cont_2

Note 9 - Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule Of Future Minimum Payments For Lease Obligations [Table Text Block]	Years ending December 31: (In thousands) Capital Operating Total Lease 2018 (remaining three months) $ 143 $ 2,776 $ 2,919 2019 513 9,966 10,479 2020 199 7,675 7,874 2021 3 7,237 7,240 2022 — 7,410 7,410 Thereafter — 3,270 3,270 Total future minimum payments $ 858 $ 38,334 $ 39,192 Less: amount representing interest (46 ) Present value of minimum lease payments 812 Less: current portion (503 ) Long-term portion $ 309

Note 10 - Revenue Recognition_2

Note 10 - Revenue Recognition and Contract Assets and Liabilities (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended September 30, (In thousands) 2018 2017 Renewable Licenses Grants and Total Renewable Licenses Grants and Total United States $ 4,884 $ — $ 626 $ 5,510 $ 5,873 $ — $ 6,141 $ 12,014 Europe 1,175 142 3,908 5,225 2,314 1,022 3,935 7,271 Asia 3,544 — — 3,544 2,773 — 125 2,898 South America 36 — 551 587 36 — 1,978 2,014 Other — — — — — — — — $ 9,639 $ 142 $ 5,085 $ 14,866 $ 10,996 $ 1,022 $ 12,179 $ 24,197 Nine Months Ended September 30, (In thousands) 2018 2017 Renewable Licenses Grants and Total Renewable Licenses Grants and Total United States $ 9,185 $ — $ 6,457 $ 15,642 $ 8,871 $ 2,673 $ 15,510 $ 27,054 Europe 6,596 18,466 11,723 36,785 5,621 1,468 9,295 16,384 Asia 5,335 — 1,000 6,335 14,242 2,633 375 17,250 South America 251 — 1,945 2,196 180 — 1,978 2,158 Other 100 — — 100 11 — — 11 $ 21,467 $ 18,466 $ 21,125 $ 61,058 $ 28,925 $ 6,774 $ 27,158 $ 62,857
Revenue in Connection with Significant Revenue Agreement [Table Text Block]	Three Months Ended September 30, (In thousands) 2018 2017 Renewable Licenses Grants and Total Renewable Licenses Grants and Total DSM - related party $ 17 $ (39 ) $ 1,748 $ 1,726 $ — $ 703 $ 634 $ 1,337 Givaudan 525 — 1,500 2,025 1,331 — 1,500 2,831 Firmenich 904 181 1,212 2,297 4,525 319 1,351 6,195 Nenter — — — — 1,678 — — 1,678 DARPA — — 241 241 — — 1,252 1,252 Subtotal revenue from significant revenue agreements 1,446 142 4,701 6,289 7,534 1,022 4,737 13,293 Revenue from all other customers 8,193 — 384 8,577 3,462 — 7,442 10,904 Total revenue from all customers $ 9,639 $ 142 $ 5,085 $ 14,866 $ 10,996 $ 1,022 $ 12,179 $ 24,197 Nine Months Ended September 30, (In thousands) 2018 2017 Renewable Licenses Grants and Total Renewable Licenses Grants and Total DSM - related party $ 17 $ 18,248 $ 5,611 $ 23,876 $ 10 $ 703 $ 783 $ 1,496 Givaudan 3,710 — 4,358 8,068 1,950 — 4,500 6,450 Firmenich 1,110 218 3,698 5,026 6,178 765 4,562 11,505 Nenter — — 1,000 1,000 8,003 2,633 — 10,636 DARPA — — 5,278 5,278 — — 6,894 6,894 Subtotal revenue from significant revenue agreements 4,837 18,466 19,945 43,248 16,141 4,101 16,739 36,981 Revenue from all other customers 16,630 — 1,180 17,810 12,784 2,673 10,419 25,876 Total revenue from all customers $ 21,467 $ 18,466 $ 21,125 $ 61,058 $ 28,925 $ 6,774 $ 27,158 $ 62,857
Contract with Customer, Asset and Liability [Table Text Block]	(In thousands) September 30, December 31, Unbilled receivable, current $ 56 $ 9,340 Unbilled receivable, noncurrent $ 9,767 $ 7,940 Deferred revenue, current $ 6,698 $ 4,880 Deferred revenue, noncurrent $ 383 (1) $ 383 (1) Accounts receivable, net $ 35,564 $ 24,281
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]	(In thousands) As of September 30, 2018 Remaining 2018 $ 3,592 2019 9,742 2020 7,742 2021 and thereafter 672 Total from all customers $ 21,748

Note 11 - Related Party Trans_2

Note 11 - Related Party Transactions (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Related Party Accounts Receivables [Table Text Block]	(In thousands) September 30, 2018 December 31, 2017 Accounts receivable, net: DSM $ 20,419 $ 3,483 Novvi 24 1,607 Total 120 238 $ 20,563 $ 5,328 Unbilled receivable, current: DSM $ 56 $ 9,340 Unbilled receivable, noncurrent: DSM $ 9,767 $ 7,940

Note 12 - Stock-based Compens_2

Note 12 - Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity [Table Text Block]	Quantity of Weighted- Weighted- Aggregate Outstanding - December 31, 2017 1,338,367 $ 33.40 7.7 $ 97 Granted 4,296,337 $ 5.18 Exercised (61,750 ) $ 3.68 Forfeited or expired (123,253 ) $ 28.18 Outstanding - September 30, 2018 5,449,701 $ 11.60 9.0 $ 13,721 Vested or expected to vest after September 30, 2018 5,031,524 $ 12.14 8.9 $ 12,552 Exercisable at September 30, 2018 942,636 $ 41.25 6.7 $ 1,536
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	Quantity of Weighted- Weighted- Outstanding - December 31, 2017 683,554 $ 8.62 1.4 Awarded 4,993,022 $ 5.38 RSUs released (226,129 ) $ 10.38 RSUs forfeited (126,355 ) $ 6.16 Outstanding - September 30, 2018 5,324,092 $ 5.57 1.8 Vested or expected to vest after September 30, 2018 5,065,108 $ 5.57 1.8
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Three Months Ended Nine Months Ended (In thousands) 2018 2017 2018 2017 Research and development $ 495 $ 395 $ 1,191 $ 1,320 Sales, general and administrative 2,442 863 4,924 2,622 Total stock-based compensation expense $ 2,937 $ 1,258 $ 6,115 $ 3,942
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Expected dividend yield — % — % — % — % Risk-free interest rate 2.8 % 2.0 % 2.7 % 2.0 % Expected term (in years) 6.87 6.20 6.85 6.10 Expected volatility 79.1 % 92.2 % 79.6 % 81.6 %
Performance-based Stock Options [Member]
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Stock Option Award with Performance and Market Vesting Conditions: Fair value of the Company’s common stock on grant date $ 5.08 Expected volatility 70 % Risk-free interest rate 2.75 % Dividend yield 0.0 %

Note 1 - Basis of Presentatio_3

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Sep. 30, 2018	Jan. 01, 2018
Working Capital		$ (59,600)	$ (105,600)
Retained Earnings (Accumulated Deficit), Ending Balance		(1,206,767)	(1,367,235)
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total			21,500
Long-term Debt, Total		165,377	171,117
Long-term Debt, Current Maturities, Including Due to Related Parties		$ 56,943	108,924
Convertible Debt, Total			23,300
Long-term Debt, Maturities, Repayments of Principal and Interest in Next 15 Months			111,400
Long Term Debt, Convertible Into Common Stock Upon Maturity			25,000
Long-term Debt, Maturities, Repayments of Interest in Next 15 Months			15,700
Cash, Cash Equivalents, and Short-term Investments, Total			$ 19,000
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		35.00%
Scenario, Forecast [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%
Accounting Standards Update 2014-09 [Member]
Retained Earnings (Accumulated Deficit), Ending Balance				$ (800)
Accounting Standards Update 2016-01 [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption				$ (1,400)

Note 1 - Basis of Presentatio_4

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies - Adoption of ASC 606 (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues	$ 14,866	$ 24,197	$ 61,058	$ 62,857
Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]
Revenues	101		(17,911)
Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Revenues	14,967		43,147
Product [Member]
Revenues	9,639	10,996	21,467	28,925
Product [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]
Revenues
Product [Member] | Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Revenues	9,639		21,467
Licenses and Royalties [Member]
Revenues	142	1,022	18,466	6,774
Licenses and Royalties [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]
Revenues	1,656		(14,091)
Licenses and Royalties [Member] | Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Revenues	1,798		4,375
Grants and Collaborations [Member]
Revenues	5,085	$ 12,179	21,125	$ 27,158
Grants and Collaborations [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]
Revenues	(1,555)		(3,820)
Grants and Collaborations [Member] | Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Revenues	$ 3,530		$ 17,305

Note 2 - Balance Sheet Detail_2

Note 2 - Balance Sheet Details (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Property, Plant and Equipment, Net, Ending Balance	$ 16,622		$ 16,622		$ 13,892
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance	104,520		104,520		105,829
Capitalized Computer Software, Additions	500			$ 2,100
Depreciation, Depletion and Amortization, Total			3,957	8,124
Property, Plant and Equipment, Including Capital Leases [Member]
Depreciation, Depletion and Amortization, Total	1,000	$ 2,700	4,000	$ 8,100
Capital Lease Obligations [Member]
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance	2,100		2,100		1,600
Capital Lease Obligations [Member] | Machinery and Equipment, Furniture and Office Equipment Under Capital Lease [Member]
Property, Plant and Equipment, Net, Ending Balance	$ 4,900		$ 4,900		$ 4,200

Note 2 - Balance Sheet Detail_3

Note 2 - Balance Sheet Details - Inventory, Current (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Raw materials	$ 1,129	$ 819
Work-in-process	929	364
Finished goods	4,202	4,225
Inventories	$ 6,260	$ 5,408

Note 2 - Balance Sheet Detail_4

Note 2 - Balance Sheet Details - Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Property, plant and equipment	$ 121,142	$ 119,721
Less: accumulated depreciation and amortization	(104,520)	(105,829)
Property, plant and equipment, net	16,622	13,892
Machinery and Equipment [Member]
Property, plant and equipment	46,725	49,277
Leasehold Improvements [Member]
Property, plant and equipment	40,703	40,036
Computer Equipment and Software [Member]
Property, plant and equipment	10,666	9,555
Furniture and Office Equipment, Vehicles and Land [Member]
Property, plant and equipment	3,705	3,415
Construction in Progress [Member]
Property, plant and equipment	$ 19,343	$ 17,438

Note 2 - Balance Sheet Detail_5

Note 2 - Balance Sheet Details - Other Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Contingent consideration	$ 7,805	$ 8,151
Prepaid royalty	6,847	7,409
Equity investment in SweeGen	5,313	3,233
Deposits	4,171	2,462
Goodwill	560	560
Other	1,861	825
Other assets	$ 26,557	$ 22,640

Note 2 - Balance Sheet Detail_6

Note 2 - Balance Sheet Details - Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Payroll and related expenses	$ 9,774	$ 7,238
Accrued interest	6,010	8,213
SMA relocation accrual	2,964	3,587
Tax-related liabilities	2,154	5,837
Professional services	1,402	1,894
Contract termination	1,000
Other	3,959	2,633
Total accrued and other current liabilities	$ 27,263	$ 29,402

Note 3 - Fair Value Measureme_3

Note 3 - Fair Value Measurement (Details Textual) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Equity Securities, FV-NI	$ 5,313		$ 3,233
Equity Securities, FV-NI, Unrealized Gain	$ 3,460
SweeGen Common Stock [Member]
Equity Securities, Number of Unregistered Shares Hold	850,115
Equity Securities, FV-NI, Unrealized Gain	$ 1,700	$ 3,500
SweeGen Common Stock [Member] | Other Noncurrent Assets [Member]
Equity Securities, FV-NI	$ 5,300		$ 2,000

Note 3 - Fair Value Measureme_4

Note 3 - Fair Value Measurement - Fair Value, Assets, and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Equity investment in SweeGen	$ 5,313	$ 3,233
Fair Value, Measurements, Recurring [Member]
Money market funds		53,199
Certificates of deposit		7,813
Equity investment in SweeGen	5,313
Total assets measured and recorded at fair value	5,313	61,012
Embedded derivatives in connection with the issuance of debt and equity instruments	9,379	4,203
Freestanding derivative instruments in connection with the issuance of equity instruments	89,283	115,775
Total liabilities measured and recorded at fair value	98,662	119,978
Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Money market funds		53,199
Certificates of deposit		7,813
Equity investment in SweeGen
Total assets measured and recorded at fair value		61,012
Embedded derivatives in connection with the issuance of debt and equity instruments
Freestanding derivative instruments in connection with the issuance of equity instruments
Total liabilities measured and recorded at fair value
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member]
Money market funds
Certificates of deposit
Equity investment in SweeGen	5,313
Total assets measured and recorded at fair value	5,313
Embedded derivatives in connection with the issuance of debt and equity instruments
Freestanding derivative instruments in connection with the issuance of equity instruments
Total liabilities measured and recorded at fair value
Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Money market funds
Certificates of deposit
Equity investment in SweeGen
Total assets measured and recorded at fair value
Embedded derivatives in connection with the issuance of debt and equity instruments	9,379	4,203
Freestanding derivative instruments in connection with the issuance of equity instruments	89,283	115,775
Total liabilities measured and recorded at fair value	$ 98,662	$ 119,978

Note 3 - Fair Value Measureme_5

Note 3 - Fair Value Measurement - Reconciliation for Compound Embedded Derivative Liability (Details) - Fair Value, Inputs, Level 3 [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2018USD ($)
Derivative Liability, Equity-related [Member]
Balance, compound embedded derivative liabilities	$ 112,368
Change in fair value of derivative liabilities	49,442
Derecognition upon extinguishment of derivative liabilities	(85,912)
Balance, compound embedded derivative liabilities	75,898
Derivative Liability, Debt-related [Member]
Balance, compound embedded derivative liabilities	7,610
Change in fair value of derivative liabilities	15,154
Derecognition upon extinguishment of derivative liabilities
Balance, compound embedded derivative liabilities	22,764
Derivative Financial Instruments, Liabilities [Member]
Balance, compound embedded derivative liabilities	119,978
Change in fair value of derivative liabilities	64,596
Derecognition upon extinguishment of derivative liabilities	(85,912)
Balance, compound embedded derivative liabilities	$ 98,662

Note 3 - Fair Value Measureme_6

Note 3 - Fair Value Measurement - Market-based Assumption and Estimates for Compound Embedded Derivative Liabilities Valuation (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2018$ / shares	Dec. 31, 2017$ / shares
Share Price	$ 7.94	$ 3.75
Measurement Input, Probability of Change in Control [Member]
Risk-free interest rate		0.05
Minimum [Member]
Estimated conversion dates	2,018	2,018
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Risk-free interest rate	0.0212	0.0168
Minimum [Member] | Measurement Input, Risk-adjusted Yields [Member]
Risk-free interest rate	0.139	0.184
Minimum [Member] | Measurement Input, Price Volatility [Member]
Risk-free interest rate	0.45	0.45
Minimum [Member] | Measurement Input, Probability of Change in Control [Member]
Risk-free interest rate	0
Minimum [Member] | Measurement Input, Credit Spread [Member]
Risk-free interest rate	0.1169	0.1663
Maximum [Member]
Estimated conversion dates	2,025	2,025
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Risk-free interest rate	0.0301	0.024
Maximum [Member] | Measurement Input, Risk-adjusted Yields [Member]
Risk-free interest rate	0.2403	0.2853
Maximum [Member] | Measurement Input, Price Volatility [Member]
Risk-free interest rate	0.8	0.8
Maximum [Member] | Measurement Input, Probability of Change in Control [Member]
Risk-free interest rate	0.05
Maximum [Member] | Measurement Input, Credit Spread [Member]
Risk-free interest rate	0.2165	0.267

Note 3 - Fair Value Measureme_7

Note 3 - Fair Value Measurement - Financial Assets and Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Total debt	$ 166,218	$ 156,900
Reported Value Measurement [Member]
Total debt	$ 171,117	$ 165,377

Note 4 - Debt (Details Textual)

Note 4 - Debt (Details Textual) - USD ($)	Jun. 29, 2018	Sep. 30, 2018	Sep. 30, 2017	Aug. 31, 2018	Jul. 31, 2018	Oct. 31, 2015	May 31, 2014
Repayments of Long-term Debt, Total		$ 41,970,000	$ 26,708,000
Loan Annual Amortization Percentage of Loan Accounts Outstanding	2.50%
Debt Instrument, Facility Charge, Percentage		4.00%
Debt Instrument, Origination Fee Amount		$ 1,400,000
Debt Instrument, Funded Amount and Other Closing Costs		200,000
Debt Instrument, Agency Fee Amount Per Quarter		25,000
Unamortized Debt Issuance Expense		$ 1,600,000
Minimum [Member] | Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate	4.00%
Maximum [Member] | Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate	6.25%
Convertible Senior Notes, 9.5% [Member]
Debt Instrument, Interest Rate, Stated Percentage						2015.00%
Rule 144A Convertible Note Offering [Member] | Convertible Debt Securities [Member]
Debt Instrument, Interest Rate, Effective Percentage							2014.00%
August 2013 Convertible Notes [Member]
Debt Instrument, Convertible, Conversion Price				$ 4.40	$ 5.2977
Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Loan and Security Agreement [Member]
Repayments of Long-term Debt, Total	$ 27,300,000
Great American Capital Partners, LLC [Member] | Loan and Security Agreement [Member]
Debt Instrument, Face Amount	36,000,000
Line of Credit Facility, Maximum Borrowing Capacity	$ 35,000,000

Note 4 - Debt - Debt Components

Note 4 - Debt - Debt Components (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Debt, principal	$ 192,621	$ 195,819
Unamortized Debt Discount	(21,504)	(30,442)
Debt	171,117	165,377
Debt, current	108,924	56,943
Debt, noncurrent	62,193	108,434
Convertible Debt [Member]
Debt, principal	66,307	70,900
Unamortized Debt Discount	(6,422)	(12,985)
Debt	59,885	57,915
Convertible Debt [Member] | The 2015 144A Notes [Member]
Debt, principal	37,887	37,887
Unamortized Debt Discount	(3,268)	(6,872)
Debt	34,619	31,015
Convertible Debt [Member] | The 2014 144A Notes [Member]
Debt, principal	24,004	24,004
Unamortized Debt Discount	(1,445)	(3,170)
Debt	22,559	20,834
Convertible Debt [Member] | December 2017 Convertible Note [Member]
Debt, principal		5,000
Unamortized Debt Discount		(25)
Debt		4,975
Convertible Debt [Member] | August 2013 Convertible Notes [Member]
Debt, principal	4,416	4,009
Unamortized Debt Discount	(1,709)	(2,918)
Debt	2,707	1,091
Loans Payable [Member]
Debt, principal	52,769	47,410
Unamortized Debt Discount	(7,082)	(6,513)
Debt	45,687	40,897
Loans Payable [Member] | Great American Capital Partners, LLC Term Loan Facility [Member]
Debt, principal	36,000
Unamortized Debt Discount	(1,489)
Debt	34,511
Loans Payable [Member] | Senior Secured Convertible Note [Member]
Debt, principal		28,566
Unamortized Debt Discount		(253)
Debt		28,313
Loans Payable [Member] | Ginkgo Collaboration Note [Member]
Debt, principal	12,000	12,000
Unamortized Debt Discount	(4,390)	(4,983)
Debt	7,610	7,017
Loans Payable [Member] | Other Loans Payable [Member]
Debt, principal	4,643	6,463
Unamortized Debt Discount	(1,203)	(1,277)
Debt	3,440	5,186
Loans Payable [Member] | Other Credit Facilities [Member]
Debt, principal	126	381
Unamortized Debt Discount
Debt	126	381
Nonrelated Party Debt [Member]
Debt, principal	119,076	118,310
Unamortized Debt Discount	(13,504)	(19,498)
Debt	105,572	98,812
Related Party Convertible Notes [Member]
Debt, principal	48,039	50,116
Unamortized Debt Discount	(1,526)	(2,905)
Debt	46,513	47,211
Related Party Convertible Notes [Member] | The 2014 144A Notes [Member]
Debt, principal	24,705	24,705
Unamortized Debt Discount	(1,731)	(3,784)
Debt	22,974	20,921
Related Party Convertible Notes [Member] | August 2013 Convertible Notes [Member]
Debt, principal	23,334	21,711
Unamortized Debt Discount	205	897
Debt	23,539	22,608
Related Party Convertible Notes [Member] | Secured R&D Notes [Member]
Debt, principal		3,700
Unamortized Debt Discount		(18)
Debt		3,682
Related Party Loan Payable [Member]
Debt, principal	25,506	27,393
Unamortized Debt Discount	(6,474)	(8,039)
Debt	19,032	19,354
Related Party Loan Payable [Member] | Other Loans Payable [Member]
Debt, principal	506	393
Unamortized Debt Discount
Debt	506	393
Related Party Loan Payable [Member] | DSM Note [Member]
Debt, principal	25,000	25,000
Unamortized Debt Discount	(6,474)	(8,039)
Debt	18,526	16,961
Related Party Loan Payable [Member] | Private Placement February 2016 [Member]
Debt, principal		2,000
Unamortized Debt Discount
Debt		2,000
Related Party Debt [Member]
Debt, principal	73,545	77,509
Unamortized Debt Discount	(8,000)	(10,944)
Debt	$ 65,545	$ 66,565

Note 4 - Debt - Long-term Debt

Note 4 - Debt - Long-term Debt Instruments (Details) $ in Thousands	Sep. 30, 2018USD ($)
2018 (remaining three months)	$ 6,023
2,019	106,409
2,020	11,415
2,021	61,699
2,022	13,416
Thereafter	2,565
Total future minimum payments	201,527
Less: amount representing interest	(31,792)
Add: amount mandatorily convertible into common stock upon maturity	(24,970)
Less: future conversion of accrued interest to principal	(2,083)
Present value of minimum debt payments	192,622
Less: current portion of debt principal	(117,592)
Noncurrent portion of debt principal	75,030
Convertible Debt [Member]
2018 (remaining three months)	2,580
2,019	69,333
2,020
2,021
2,022
Thereafter
Total future minimum payments	71,913
Less: amount representing interest	(5,159)
Add: amount mandatorily convertible into common stock upon maturity
Less: future conversion of accrued interest to principal	(447)
Present value of minimum debt payments	66,307
Less: current portion of debt principal	(66,307)
Noncurrent portion of debt principal
Loans Payable and Credit Facilities [Member]
2018 (remaining three months)	1,508
2,019	9,068
2,020	8,915
2,021	34,178
2,022	13,416
Thereafter	2,565
Total future minimum payments	69,650
Less: amount representing interest	(16,881)
Add: amount mandatorily convertible into common stock upon maturity
Less: future conversion of accrued interest to principal
Present value of minimum debt payments	52,769
Less: current portion of debt principal	(2,739)
Noncurrent portion of debt principal	50,030
Related Party Loan Payable [Member]
2018 (remaining three months)	803
2,019	25,508
2,020
2,021
2,022
Thereafter
Total future minimum payments	26,311
Less: amount representing interest	(1,606)
Add: amount mandatorily convertible into common stock upon maturity	(24,970)
Less: future conversion of accrued interest to principal	(1,636)
Present value of minimum debt payments	48,039
Less: current portion of debt principal	(48,039)
Noncurrent portion of debt principal
Related Party Loans Payable and Credit Facilities [Member]
2018 (remaining three months)	1,132
2,019	2,500
2,020	2,500
2,021	27,521
2,022
Thereafter
Total future minimum payments	33,653
Less: amount representing interest	(8,146)
Add: amount mandatorily convertible into common stock upon maturity
Less: future conversion of accrued interest to principal
Present value of minimum debt payments	25,507
Less: current portion of debt principal	(507)
Noncurrent portion of debt principal	$ 25,000

Note 5 - Mezzanine Equity (Deta

Note 5 - Mezzanine Equity (Details Textual) - $ / shares	Apr. 08, 2016	Sep. 30, 2018	Dec. 31, 2017
Share Price		$ 7.94	$ 3.75
Gates Foundation Purchase Agreement [Member]
Share Price	$ 17.10
Compound Annual Return	10.00%

Note 5 - Mezzanine Equity - Mez

Note 5 - Mezzanine Equity - Mezzanine Equity (Details) - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017
Contingently Redeemable Common Stock [Member]
Mezzanine Equity	$ 5	$ 5

Note 6 - Stockholders' Defici_2

Note 6 - Stockholders' Deficit (Details Textual)	Apr. 12, 2018USD ($)yr$ / sharesshares	Mar. 08, 2016USD ($)	Aug. 31, 2018USD ($)yr$ / sharesshares	Sep. 30, 2018USD ($)$ / sharesshares	Jun. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)$ / sharesshares	Sep. 30, 2017USD ($)	Jul. 31, 2018$ / shares
Proceeds from Warrant Exercises							$ 60,544,000
Stock Issued During Period, Shares, Warrants Exercised | shares							16,360,051
Class of Warrants or Right, Issued in Period | shares							16,184,542
Gain (Loss) on Extinguishment of Derivative Liability, Net					$ 1,900,000
Gain on Extinguishment of Derivative Liability				$ (1,782,000)	11,300,000	$ 16,036,000	$ 75,000	$ 25,489,000
At the Market Offering [Member]
Common Stock, Value, Subscriptions		$ 50,000,000		$ 0			$ 0
Commission Rate		3.00%
Stock Issued During Period, Shares, New Issues | shares				0			205,168
Proceeds from Issuance of Common Stock							$ 1,400,000
At The Market Offering, Six Months Ended [Member]
Shares Issued, Price Per Share | $ / shares				$ 6.90			$ 6.90
August 2013 Convertible Notes [Member]
Debt Instrument, Convertible, Conversion Price | $ / shares			$ 4.40						$ 5.2977
May 2017 Warrants [Member]
Proceeds from Warrant Exercises	$ 8,000,000
Stock Issued During Period, Shares, Warrants Exercised | shares	6
Class of Warrants or Right, Issued in Period | shares	3,616,174
Proceeds from Issuance of Warrants	$ 14.50
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 7
Warrants and Rights Outstanding	$ 9,400,000
Loss on Extinguishment of Derivative Liability					9,400,000
Increase (Decrease) in Derivative Liabilities					$ (21,900,000)
May 2017 Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	0.9
May 2017 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.0216
May 2017 Warrants [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input | yr	1.25
May 2017 Warrants [Member] | Measurement Input, Expected Dividend Payment [Member]
Warrants and Rights Outstanding, Measurement Input	0
May 2017 Warrants [Member] | Measurement Input, Exercise Price [Member]
Warrants and Rights Outstanding, Measurement Input	7
May 2017 Warrants [Member] | Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input	6.8
Cash Warrants and Dilution Warrants [Member]
Proceeds from Warrant Exercises			$ 46,000,000
Stock Issued During Period, Shares, Warrants Exercised | shares			12,600,000
August 2018 New Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 7.52
Warrants and Rights Outstanding			$ 30,100,000
Gain (Loss) on Extinguishment of Derivative Liability, Net			(3,600,000)
Gain on Extinguishment of Derivative Liability			26,500,000
Loss on Extinguishment of Derivative Liability			30,100,000
Increase (Decrease) in Derivative Liabilities			$ 63,300,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares			12.1
August 2018 New Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input			0.8
August 2018 New Warrants [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input | yr			1.75
August 2018 New Warrants [Member] | Measurement Input, Exercise Price [Member]
Warrants and Rights Outstanding, Measurement Input			7.52
August 2018 New Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input			0
Temasek Funding Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares				1,889,986			1,889,986
Class of Warrant or Right, Additional Number of Securities Called by Warrants or Rights | shares			471,204

Note 6 - Stockholders' Defici_3

Note 6 - Stockholders' Deficit - Warrant Activity (Details)	9 Months Ended
	Sep. 30, 2018shares
Number outstanding, beginning balance (in shares)	29,921,844
Additional Warrants Issued (in shares)	16,184,542
Exercises (in shares)	(16,360,051)
Number outstanding, ending balance (in shares)	29,746,335
Warrant 1 [Member]
Number outstanding, beginning balance (in shares)	81,197
Additional Warrants Issued (in shares)
Exercises (in shares)
Number outstanding, ending balance (in shares)	81,197
Warrant 2 [Member]
Number outstanding, beginning balance (in shares)	2,082,010
Additional Warrants Issued (in shares)	471,204
Exercises (in shares)
Number outstanding, ending balance (in shares)	2,553,214
Warrant 3 [Member]
Number outstanding, beginning balance (in shares)	171,429
Additional Warrants Issued (in shares)
Exercises (in shares)
Number outstanding, ending balance (in shares)	171,429
Warrant 4 [Member]
Number outstanding, beginning balance (in shares)	18,042,568
Additional Warrants Issued (in shares)
Exercises (in shares)	(10,784,933)
Number outstanding, ending balance (in shares)	7,257,635
Warrant 5 [Member]
Number outstanding, beginning balance (in shares)	9,543,234
Additional Warrants Issued (in shares)
Exercises (in shares)	(5,575,118)
Number outstanding, ending balance (in shares)	3,968,116
Warrant 6 [Member]
Number outstanding, beginning balance (in shares)
Additional Warrants Issued (in shares)	3,616,174
Exercises (in shares)
Number outstanding, ending balance (in shares)	3,616,174
Warrant 7 [Member]
Number outstanding, beginning balance (in shares)
Additional Warrants Issued (in shares)	12,097,164
Exercises (in shares)
Number outstanding, ending balance (in shares)	12,097,164
Warrant 8 [Member]
Number outstanding, beginning balance (in shares)	1,406
Additional Warrants Issued (in shares)
Exercises (in shares)
Number outstanding, ending balance (in shares)	1,406

Note 7 - Variable-interest En_3

Note 7 - Variable-interest Entities and Unconsolidated Investments - Variable Interest Entities (Details) - Variable Interest Entity, Primary Beneficiary [Member] - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Assets	$ 38,422	$ 36,781
Liabilities	$ 1,960	$ 3,187

Note 7 - Variable-interest En_4

Note 7 - Variable-interest Entities and Unconsolidated Investments - Unconsolidated Investments (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Equity investment in SweeGen	$ 5,313	$ 3,233
Novvi LLC [Member]
Equity-method investment, percentage	20.00%
Equity-method investment
Total Amyris Biosolutions B.V. [Member]
Equity-method investment, percentage	25.00%
Equity-method investment
SweeGen, Inc. [Member]
SweeGen, Inc.	3.00%
Equity investment in SweeGen	$ 5,313	$ 3,233

Note 8 - Net Loss Per Share A_3

Note 8 - Net Loss Per Share Attributable to Common Stockholders (Details Textual) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Earnings Per Share, Diluted, Total	$ 60,966,071	$ 37,529,694	$ 55,735,571	$ 27,280,894
Previously Reported [Member]
Net Income (Loss) Available to Common Stockholders, Diluted, Total				$ (125.9)
Earnings Per Share, Diluted, Total				$ (4.61)

Note 8 - Net Loss Per Share A_4

Note 8 - Net Loss Per Share Attributable to Common Stockholders - Calculation of Basic and Diluted Net Loss Per Share of Common Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Net loss attributable to Amyris, Inc.	$ (68,321)	$ (33,861)	$ (158,284)	$ (70,612)
Less deemed dividend on capital distribution to related parties				(8,648)
Less deemed dividend related to beneficial conversion feature on Series A preferred stock				(562)
Less deemed dividend related to beneficial conversion feature on Series B preferred stock		(634)		(634)
Less deemed dividend related to beneficial conversion feature on Series D preferred stock		(5,757)		(5,757)
Less cumulative dividends on Series A and B preferred stock	(279)	(2,567)	(1,073)	(4,242)
Net loss attributable to Amyris, Inc. common stockholders, basic and diluted	$ (68,600)	$ (42,819)	$ (159,357)	$ (90,455)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted (in shares)	60,966,071	37,529,694	55,735,571	27,280,894
Loss per share attributable to common stockholders, basic and diluted (in dollars per share)	$ (1.13)	$ (1.14)	$ (2.86)	$ (3.32)

Note 8 - Net Loss Per Share A_5

Note 8 - Net Loss Per Share Attributable to Common Stockholders - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares		3 Months Ended		9 Months Ended
		Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Antidilutive securities (in shares)		49,113,091	40,985,122	49,113,091	40,985,122
Stock Options to Purchase Common Stock [Member]
Antidilutive securities (in shares)		5,449,701	949,023	5,449,701	949,023
Convertible Promissory Notes [Member]
Antidilutive securities (in shares)	[1]	9,397,134	8,133,594	9,397,134	8,133,594
Period-end Common Stock Warrants [Member]
Antidilutive securities (in shares)		25,986,432	31,303,080	25,986,432	31,303,080
Restricted Stock Units (RSUs) [Member]
Antidilutive securities (in shares)		5,324,092	599,425	5,324,092	599,425
Period-end Preferred Stock [Member]
Antidilutive securities (in shares)		2,955,732		2,955,732
[1]	The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of the respective period end dates. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding.

Note 9 - Commitments and Cont_3

Note 9 - Commitments and Contingencies (Details Textual) - Chattel Mortgage [Member] R$ in Millions, $ in Millions	9 Months Ended		12 Months Ended
	Sep. 30, 2018USD ($)	Sep. 30, 2018BRL (R$)	Dec. 31, 2017USD ($)	Dec. 31, 2017BRL (R$)
FINEP Credit Facility [Member]
Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired | $	$ 1.5		$ 1.8
FINEP Credit Facility [Member]
Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired | R$		R$ 6		R$ 6

Note 9 - Commitments and Cont_4

Note 9 - Commitments and Contingencies - Future Minimum Payments for Lease Obligations (Details) $ in Thousands	Sep. 30, 2018USD ($)
2018 (remaining three months)	$ 143
2018 (remaining three months)	2,776
2018 (remaining three months)	2,919
Capital leases 2019	513
Operating leases 2019	9,966
Total lease obligations 2019	10,479
Capital leases 2020	199
Operating leases 2020	7,675
Total lease obligations 2020	7,874
Capital leases 2021	3
Operating leases 2021	7,237
Total lease obligations 2021	7,240
Capital leases 2022
Operating leases 2022	7,410
Total lease obligations 2022	7,410
Capital leases thereafter
Operating leases thereafter	3,270
Total lease obligations thereafter	3,270
Total future minimum capital lease payments	858
Total future minimum operating lease payments	38,334
Total future minimum lease payments	39,192
Less: amount representing interest	(46)
Present value of minimum lease payments	812
Less: current portion	(503)
Long-term portion	$ 309

Note 10 - Revenue Recognition_3

Note 10 - Revenue Recognition and Contract Assets and Liabilities (Details Textual) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Contract with Customer, Asset, Reclassified to Receivable	$ 7,500
Increase (Decrease) in Contract with Customer, Liability	1,014	$ 1,113
Contract with Customer, Liability, Current	6,698		$ 4,880
Revenue, Remaining Performance Obligation, Constrained Variable Consideration, Amount	17,400
Royalty [Member]
Contract with Customer, Liability, Revenue Recognized	3,300
Accounting Standards Update 2014-09 [Member]
Increase (Decrease) in Contract with Customer, Liability	1,800
Contract with Customer, Liability, Current	$ 800

Note 10 - Revenue Recognition_4

Note 10 - Revenue Recognition and Contract Assets and Liabilities - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues	$ 14,866	$ 24,197	$ 61,058	$ 62,857
Product [Member]
Revenues	9,639	10,996	21,467	28,925
Licenses and Royalties [Member]
Revenues	142	1,022	18,466	6,774
Grants and Collaborations [Member]
Revenues	5,085	12,179	21,125	27,158
UNITED STATES
Revenues	5,510	12,014	15,642	27,054
UNITED STATES | Product [Member]
Revenues	4,884	5,873	9,185	8,871
UNITED STATES | Licenses and Royalties [Member]
Revenues				2,673
UNITED STATES | Grants and Collaborations [Member]
Revenues	626	6,141	6,457	15,510
Europe [Member]
Revenues	5,225	7,271	36,785	16,384
Europe [Member] | Product [Member]
Revenues	1,175	2,314	6,596	5,621
Europe [Member] | Licenses and Royalties [Member]
Revenues	142	1,022	18,466	1,468
Europe [Member] | Grants and Collaborations [Member]
Revenues	3,908	3,935	11,723	9,295
Asia [Member]
Revenues	3,544	2,898	6,335	17,250
Asia [Member] | Product [Member]
Revenues	3,544	2,773	5,335	14,242
Asia [Member] | Licenses and Royalties [Member]
Revenues				2,633
Asia [Member] | Grants and Collaborations [Member]
Revenues		125	1,000	375
South America [Member]
Revenues	587	2,014	2,196	2,158
South America [Member] | Product [Member]
Revenues	36	36	251	180
South America [Member] | Licenses and Royalties [Member]
Revenues
South America [Member] | Grants and Collaborations [Member]
Revenues	551	1,978	1,945	1,978
Other Area [Member]
Revenues			100	11
Other Area [Member] | Product [Member]
Revenues			100	11
Other Area [Member] | Licenses and Royalties [Member]
Revenues
Other Area [Member] | Grants and Collaborations [Member]
Revenues

Note 10 - Revenue Recognition_5

Note 10 - Revenue Recognition and Contract Assets and Liabilities - Revenue in Connection With Significant Revenue Agreement (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues	$ 14,866	$ 24,197	$ 61,058	$ 62,857
Significant Revenue Agreement [Member]
Revenues	6,289	13,293	43,248	36,981
DSM International B.V. [Member] | Significant Revenue Agreement [Member]
Revenues	1,726	1,337	23,876	1,496
Givaudan International, SA [Member] | Significant Revenue Agreement [Member]
Revenues	2,025	2,831	8,068	6,450
Firmenich [Member] | Significant Revenue Agreement [Member]
Revenues	2,297	6,195	5,026	11,505
Nenter & Co., Inc. [Member] | Significant Revenue Agreement [Member]
Revenues		1,678	1,000	10,636
DARPA [Member] | Significant Revenue Agreement [Member]
Revenues	241	1,252	5,278	6,894
All Other Customers [Member]
Revenues	8,577	10,904	17,810	25,876
Renewable Products [Member]
Revenues	9,639	10,996	21,467	28,925
Renewable Products [Member] | Significant Revenue Agreement [Member]
Revenues	1,446	7,534	4,837	16,141
Renewable Products [Member] | DSM International B.V. [Member] | Significant Revenue Agreement [Member]
Revenues	17		17	10
Renewable Products [Member] | Givaudan International, SA [Member] | Significant Revenue Agreement [Member]
Revenues	525	1,331	3,710	1,950
Renewable Products [Member] | Firmenich [Member] | Significant Revenue Agreement [Member]
Revenues	904	4,525	1,110	6,178
Renewable Products [Member] | Nenter & Co., Inc. [Member] | Significant Revenue Agreement [Member]
Revenues		1,678		8,003
Renewable Products [Member] | DARPA [Member] | Significant Revenue Agreement [Member]
Revenues
Renewable Products [Member] | All Other Customers [Member]
Revenues	8,193	3,462	16,630	12,784
Licenses and Royalties [Member]
Revenues	142	1,022	18,466	6,774
Licenses and Royalties [Member] | Significant Revenue Agreement [Member]
Revenues	142	1,022	18,466	4,101
Licenses and Royalties [Member] | DSM International B.V. [Member] | Significant Revenue Agreement [Member]
Revenues	(39)	703	18,248	703
Licenses and Royalties [Member] | Givaudan International, SA [Member] | Significant Revenue Agreement [Member]
Revenues
Licenses and Royalties [Member] | Firmenich [Member] | Significant Revenue Agreement [Member]
Revenues	181	319	218	765
Licenses and Royalties [Member] | Nenter & Co., Inc. [Member] | Significant Revenue Agreement [Member]
Revenues				2,633
Licenses and Royalties [Member] | DARPA [Member] | Significant Revenue Agreement [Member]
Revenues
Licenses and Royalties [Member] | All Other Customers [Member]
Revenues				2,673
Grants and Collaborations [Member]
Revenues	5,085	12,179	21,125	27,158
Grants and Collaborations [Member] | Significant Revenue Agreement [Member]
Revenues	4,701	4,737	19,945	16,739
Grants and Collaborations [Member] | DSM International B.V. [Member] | Significant Revenue Agreement [Member]
Revenues	1,748	634	5,611	783
Grants and Collaborations [Member] | Givaudan International, SA [Member] | Significant Revenue Agreement [Member]
Revenues	1,500	1,500	4,358	4,500
Grants and Collaborations [Member] | Firmenich [Member] | Significant Revenue Agreement [Member]
Revenues	1,212	1,351	3,698	4,562
Grants and Collaborations [Member] | Nenter & Co., Inc. [Member] | Significant Revenue Agreement [Member]
Revenues			1,000
Grants and Collaborations [Member] | DARPA [Member] | Significant Revenue Agreement [Member]
Revenues	241	1,252	5,278	6,894
Grants and Collaborations [Member] | All Other Customers [Member]
Revenues	$ 384	$ 7,442	$ 1,180	$ 10,419

Note 10 - Revenue Recognition_6

Note 10 - Revenue Recognition and Contract Assets and Liabilities - Contract Balances (Details) - USD ($) $ in Thousands		Sep. 30, 2018	Dec. 31, 2017
Unbilled receivable, current		$ 56	$ 9,340
Unbilled receivable, noncurrent		9,767	7,940
Deferred revenue, current		6,698	4,880
Deferred revenue, noncurrent	[1]	383	383
Accounts receivable, net		$ 35,564	$ 24,281
[1]	As of September 30, 2018 and December 31, 2017, deferred revenue, noncurrent is presented in Other Noncurrent Liabilities in the consolidated balance sheets because of its insignificance.

Note 10 - Revenue Recognition_7

Note 10 - Revenue Recognition and Contract Assets and Liabilities - Remaining Performance Obligations (Details) $ in Thousands	Sep. 30, 2018USD ($)
Remaining performance obligation	$ 21,748

Note 10 - Revenue Recognition_8

Note 10 - Revenue Recognition and Contract Assets and Liabilities - Remaining Performance Obligations 2 (Details) $ in Thousands	Sep. 30, 2018USD ($)
Remaining performance obligation	$ 21,748
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-10-01
Remaining performance obligation	3,592
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01
Remaining performance obligation	9,742
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Remaining performance obligation	7,742
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Remaining performance obligation	$ 672

Note 11 - Related Party Trans_3

Note 11 - Related Party Transactions - Related Party Accounts Receivable (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Accounts receivable, net	$ 20,563	$ 5,328
Unbilled receivable	56	9,340
Unbilled receivable, noncurrent	9,767	7,940
DSM International B.V. [Member]
Accounts receivable, net	20,419	3,483
Unbilled receivable	56	9,340
Unbilled receivable, noncurrent	9,767	7,940
Novvi LLC [Member]
Accounts receivable, net	24	1,607
Total [Member]
Accounts receivable, net	$ 120	$ 238

Note 12 - Stock-based Compens_3

Note 12 - Stock-based Compensation (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended	9 Months Ended
	May 31, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2018	Sep. 30, 2017
Performance-based Stock Options, Grant Date Fair Value		$ 5,100,000		$ 5,100,000	$ 5,100,000
Allocated Share-based Compensation Expense, Total		$ 2,937,000	$ 1,258,000		$ 6,115,000	$ 3,942,000
Chief Executive Officer [Member]
Purchasable Shares Under Performance Based Options	3,250,000
Performance-Based Stock Options, Exercise Price				$ 5.08
Chief Executive Officer [Member] | Minimum [Member]
Performance-Based Stock Options Contingently Available for Issuance		0		0	0
Chief Executive Officer [Member] | Maximum [Member]
Performance-Based Stock Options Contingently Available for Issuance		3,250,000		3,250,000	3,250,000
Equity Incentive Plan, 2010 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	9,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee	4,000,000
Employee Stock Purchase Plan, 2010 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	1,000,000
Employee Stock Option [Member]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total		$ 35		$ 35	$ 35
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition					3 years 182 days
Performance-based Stock Options [Member]
Performance-Based Stock Options, Exercise Price					$ 5.08
Allocated Share-based Compensation Expense, Total		$ 300,000			$ 400,000

Note 12 - Stock-based Compens_4

Note 12 - Stock-based Compensation - Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Outstanding (in shares)	1,338,367
Outstanding, weighted average exercise price (in dollars per share)	$ 33.40
Outstanding, weighted average remaining contractual life (Year)	9 years	7 years 255 days
Outstanding, aggregate intrinsic value	$ 13,721	$ 97
Granted (in shares)	4,296,337
Granted, weighted average exercise price (in dollars per share)	$ 5.18
Exercised (in shares)	(61,750)
Exercised, weighted average exercise price (in dollars per share)	$ 3.68
Forfeited or expired (in shares)	(123,253)
Forfeited or expired, weighted average exercise price (in dollars per share)	$ 28.18
Outstanding (in shares)	5,449,701	1,338,367
Outstanding, weighted average exercise price (in dollars per share)	$ 11.60	$ 33.40
Vested or expected to vest (in shares)	5,031,524
Vested and expected to vest, weighted average exercise price (in dollars per share)	$ 12.14
Vested and expected to vest, weighted average remaining contractual life (Year)	8 years 328 days
Vested and expected to vest, aggregate intrinsic value	$ 12,552
Exercisable (in shares)	942,636
Exercisable, weighted average exercise price (in dollars per share)	$ 41.25
Exercisable, weighted average remaining contractual life (Year)	6 years 255 days
Exercisable, aggregate intrinsic value	$ 1,536

Note 12 - Stock-based Compens_5

Note 12 - Stock-based Compensation - Temporal Display of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Outstanding, RSUs (in shares)	683,554
Outstanding, weighted average grant-date fair value (in dollars per share)	$ 8.62
Outstanding, weighted average remaining contractual life (Year)	1 year 292 days	1 year 146 days
Awarded (in shares)	4,993,022
Awarded, weighted average grant-date fair value (in dollars per share)	$ 5.38
RSUs released (in shares)	(226,129)
RSUs released, weighted average grant-date fair value (in dollars per share)	$ 10.38
RSUs forfeited (in shares)	(126,355)
RSUs forfeited, weighted average grant-date fair value (in dollars per share)	$ 6.16
Outstanding, RSUs (in shares)	5,324,092	683,554
Outstanding, weighted average grant-date fair value (in dollars per share)	$ 5.57	$ 8.62
Vested or expected to vest (in shares)	5,065,108
Vested or expected to vest, weighted average grant-date fair value (in dollars per share)	$ 5.57
Vested or expected to vest, weighted average remaining contractual life (Year)	1 year 292 days

Note 12 - Stock-based Compens_6

Note 12 - Stock-based Compensation - Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Allocated share-based compensation expense	$ 2,937	$ 1,258	$ 6,115	$ 3,942
Research and Development Expense [Member]
Allocated share-based compensation expense	495	395	1,191	1,320
Selling, General and Administrative Expenses [Member]
Allocated share-based compensation expense	$ 2,442	$ 863	$ 4,924	$ 2,622

Note 12 - Stock-based Compens_7

Note 12 - Stock-based Compensation - Share-based Payment Award, Stock Options, Valuation Assumptions (Details) - Employee Stock Option [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Expected dividend yield
Risk-free interest rate	2.80%	2.00%	2.70%	2.00%
Expected term (in years) (Year)	6 years 317 days	6 years 73 days	6 years 310 days	6 years 36 days
Expected volatility	79.10%	92.20%	79.60%	81.60%

Note 12 - Stock-based Compens_8

Note 12 - Stock-based Compensation - Share-based Payment Award, Stock Options with Performance, Valuation Assumptions (Details) - Performance-based Stock Options [Member]	9 Months Ended
	Sep. 30, 2018$ / shares
Fair value of the Company’s common stock on grant date (in dollars per share)	$ 5.08
Expected volatility	70.00%
Risk-free interest rate	2.75%
Dividend yield	0.00%

Note 13 - Subsequent Events (De

Note 13 - Subsequent Events (Details Textual) - shares	Nov. 08, 2018	Oct. 19, 2018	Oct. 16, 2018	Sep. 30, 2018
Temasek Funding Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				1,889,986
Subsequent Event [Member] | Temasek Funding Warrant [Member]
Stock Issued During Period, Shares, New Issues		1,852,585
Tranche I Notes [Member] | Subsequent Event [Member]
Debt Conversion, Converted Instrument, Shares Issued			3,448,821
Tranche II Notes [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities	2,226,105